Publication - American Heart Association

Transcription

EXPECT
REGISTER
BY OCT. 7
TO SAVE!
THINGS
SCIENTIFIC SESSIONS PREVIEW
BIG REASONS TO ATTEND
BIG SCIENCE AND CLINICAL CONTENT
BIG SPEAKERS
BIG TECHNOLOGY
BIG LEARNING
BIG FUN IN ORLANDO
AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2015
WELCOME
DEAR COLLEAGUES,
It is our pleasure to invite you to attend
Scientific Sessions 2015 in Orlando. The
American Heart Association’s annual meeting
offers a unique opportunity to gather and
network with colleagues from around the
world in an educational and professional
environment. This event features five days of the best in
science and cardiovascular clinical practice
covering all aspects of basic, clinical,
population and translational content. The
scope and quality of the scientific exchange
make Scientific Sessions the premier
cardiovascular research and instructional
meeting in the world. Exciting changes have been made to
Scientific Sessions’ structure, and new topics
have been added to increase the educational
offerings available to attendees. Educational
sessions this year are organized in 30 areas
of interest (tracks) structured to help you find
your community within the event. New areas
of interest introduced for Sessions 2015 include
Workplace Health, Health Tech, Frontiers in
Science and Clinical Trialists.
Also new this year are the Simulation Zone,
featuring hands-on activities at the 3D Body
Interact and Mechanical Circulatory Support
Simulation, and the Genomics Boot Camp,
offering non-scientists and practitioners the
The Orange County Convention Center, in Orlando, Florida, will host Scientific Sessions 2015.
opportunity to learn about genomics through
case-based, active-learning activities.
We will continue with the very well-received
Case Theaters: Learning at the Movies, which
offer 45-minute live presentations of recorded
cases, accompanied by panel discussion. Other
highlights include an increased number of
joint sessions with professional societies from
around the world, additional MOC sessions,
Professor Rounds of posters, a poster reception
highlighting some of the best basic science
research, as well as many more.
Scientific Sessions continues to evolve and
improve with the input from our attendees
making an already great meeting even more
spectacular. We thank you for your input in the
past, and we hope you have the opportunity to
experience the enhancements to our meeting.
Most importantly, we hope the meeting
addresses the greater mission of the American
Heart Association, to reduce the burden of
cardiovascular disease.
Sincerely yours,
Frank Sellke, MD, FAHA
Chair, Committee on Scientific
Sessions Programming
Eric Peterson, MD, MPH, FAHA
Vice Chair, Committee on Scientific
Sessions Programming
scientificsessions.org | American Heart Association Scientific Sessions 2015 Preview
1
INSIDE THE
BIG
Bigger and better: Scientific Sessions 2015 highlights
Big reasons you can’t miss Scientific Sessions 2015
Scientific Sessions Week at-a-glance
BIG
1
6
8
12
TECHNOLOGY
Scientific Sessions 2015 exhibitors
Cardiovascular Expert Theaters
BIG
LEARNING
BIG
FUN IN ORLANDO
Unofficial Satellite Events SCIENCE AND CLINICAL CONTENT
Late-Breaking Clinical Trials
Clinical Science Special Reports
Scientific programming
Narrow your focus: 30 areas of interest/tracks
CME/CE information
BIG
BIG
REASONS TO ATTEND
Welcome from chair and vice chair of the
Committee on Scientific Sessions Programming
14
20
21
21
SPEAKERS
Scientific Sessions 2015 faculty
22
Welcome to Orlando
Orlando attractions
BIG
30
32
34
36
36
PLANS
Do-now checklist
40
American Heart Association
National Center
7272 Greenville Ave.
Dallas, TX 75231
214-373-6300
800-242-2453
my.americanheart.org
Registration
Convention Data Services
508-743-8517
800-748-3583
[email protected]
Housing
Travel Planners
212-532-1660
877-468-3548
[email protected]
Facility
Orange County Convention
Center
9400 Universal Blvd.
Orlando, FL 32819
occc.net
For advertising
information, visit:
[email protected]
For additional information regarding Scientific Sessions 2015, please visit scientificsessions.org.
The official American Heart Association Conference Preview is published by AHA as an exclusive service to Scientific Sessions 2015 attendees. While every effort is made to
ensure accuracy, AHA makes no warranties, expressed or implied, related to the information. Information contained herein is subject to change without notice. No part of this
publication may be reproduced, stored or transmitted without written permission from AHA.
© 2015 American Heart Association. All rights reserved.
2
American Heart Association Scientific Sessions 2015 Preview | scientificsessions.org
Add Corlanor ® to maximally tolerated doses of beta-blockers and help
give appropriate patients with stable, symptomatic chronic heart failure...
MORE HOME. LESS HOSPITAL.
Learn how you can DO MORE with Corlanor® to reduce the risk
of hospitalization for worsening heart failure
1
CorlanorHCP.com
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization
for worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction ≤ 35%, who
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and
either are on maximally tolerated doses of beta-blockers or have a
contraindication to beta-blocker use.
Important Safety Information
Contraindications: Corlanor® is contraindicated in patients with
acute decompensated heart failure, blood pressure < 90/50 mmHg,
sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular
block (unless a functioning demand pacemaker is present), a resting
heart rate < 60 bpm prior to treatment, severe hepatic impairment,
pacemaker dependence (heart rate maintained exclusively by the
pacemaker), and concomitant use of strong cytochrome P450 3A4
(CYP3A4) inhibitors.
Fetal Toxicity: Corlanor® may cause fetal toxicity when administered
to a pregnant woman based on embryo-fetal toxicity and cardiac
teratogenic effects observed in animal studies. Advise females to use
effective contraception when taking Corlanor®.
Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation.
The rate of atrial fibrillation in patients treated with Corlanor®
compared to placebo was 5% vs. 3.9% per patient-year, respectively.
Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial
fibrillation develops.
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-108642
Bradycardia and Conduction Disturbances: Bradycardia, sinus
arrest and heart block have occurred with Corlanor®. The rate of
bradycardia in patients treated with Corlanor® compared to placebo
was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per
patient-year, respectively. Risk factors for bradycardia include sinus
node dysfunction, conduction defects, ventricular dyssynchrony, and
use of other negative chronotropes. Concurrent use of verapamil or
diltiazem also increases Corlanor® exposure, contributes to heart rate
lowering, and should be avoided. Avoid use of Corlanor® in patients
with 2nd degree atrioventricular block unless a functioning demand
pacemaker is present.
Adverse Reactions: The most common adverse reactions reported
at least 1% more frequently with Corlanor® than placebo and that
occurred in more than 1% of patients treated with Corlanor® were
bradycardia (10% vs. 2.2%), hypertension or increased blood pressure
(8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous
phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).
Please see Brief Summary of full Prescribing Information
on adjacent page.
Reference: 1. Corlanor® (ivabradine) Prescribing Information, Amgen.
Corlanor® (ivabradine)
BRIEF SUMMARY OF PRESCRIBING INFORMATION
Please see package insert for full Prescribing Information
1. INDICATIONS AND USAGE
Corlanor is indicated to reduce the risk of hospitalization for
worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction
≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70
beats per minute and either are on maximally tolerated doses
of beta-blockers or have a contraindication to beta-blocker use.
4. CONTRAINDICATIONS
Corlanor is contraindicated in patients with:
• Acute decompensated heart failure
• Blood pressure less than 90/50 mmHg
• Sick sinus syndrome, sinoatrial block, or 3rd degree AV block,
unless a functioning demand pacemaker is present
• Resting heart rate less than 60 bpm prior to treatment [see
Warnings and Precautions (5.3)]
• Severe hepatic impairment [see Use in Specific Populations
(8.6)]
• Pacemaker dependence (heart rate maintained exclusively by
the pacemaker) [see Drug Interactions (7.3)]
• Concomitant use of strong cytochrome P450 3A4
(CYP3A4) inhibitors [see Drug Interactions (7.1)]
5. WARNINGS AND PRECAUTIONS
5.1 Fetal Toxicity
Corlanor may cause fetal toxicity when administered to a pregnant
woman based on findings in animal studies. Embryo-fetal toxicity
and cardiac teratogenic effects were observed in fetuses of
pregnant rats treated during organogenesis at exposures 1
to 3 times the human exposures (AUC0-24hr) at the maximum
recommended human dose (MRHD) [see Use in Specific
Populations (8.1)]. Advise females to use effective contraception
when taking Corlanor [see Use in Specific Populations (8.3)].
5.2 Atrial Fibrillation
Corlanor increases the risk of atrial fibrillation. In SHIFT, the rate
of atrial fibrillation was 5.0% per patient-year in patients treated
with Corlanor and 3.9% per patient-year in patients treated with
placebo [see Clinical Studies (14)]. Regularly monitor cardiac
rhythm. Discontinue Corlanor if atrial fibrillation develops.
5.3 Bradycardia and Conduction Disturbances
Bradycardia, sinus arrest, and heart block have occurred
with Corlanor. The rate of bradycardia was 6.0% per patientyear in patients treated with Corlanor (2.7% symptomatic;
3.4% asymptomatic) and 1.3% per patient-year in patients
treated with placebo. Risk factors for bradycardia include
sinus node dysfunction, conduction defects (e.g., 1st or 2nd
degree atrioventricular block, bundle branch block), ventricular
dyssynchrony, and use of other negative chronotropes (e.g.,
digoxin, diltiazem, verapamil, amiodarone). Concurrent use
of verapamil or diltiazem will increase Corlanor exposure,
may themselves contribute to heart rate lowering, and should
be avoided [see Clinical Pharmacology (12.3)]. Avoid use of
Corlanor in patients with 2nd degree atrioventricular block,
unless a functioning demand pacemaker is present [see
Contraindications (4) and Dosage and Administration (2)].
6. ADVERSE REACTIONS
Clinically significant adverse reactions that appear in other
sections of the labeling include:
• Fetal Toxicity [see Warnings and Precautions (5.1)]
• Atrial Fibrillation [see Warnings and Precautions (5.2)]
• Bradycardia and Conduction Disturbances [see Warnings and
Precautions (5.3)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying
conditions, adverse reaction rates observed in the clinical trials of
a drug cannot be directly compared to rates in the clinical trials of
another drug and may not reflect the rates observed in practice.
In the Systolic Heart failure treatment with the If inhibitor
ivabradine Trial (SHIFT), safety was evaluated in 3260 patients
treated with Corlanor and 3278 patients given placebo. The
median duration of Corlanor exposure was 21.5 months.
The most common adverse drug reactions in the SHIFT trial are
shown in Table 2 [see also Warnings and Precautions (5.2), (5.3)].
Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher
on Ivabradine than Placebo occurring in > 1% on ivabradine
in SHIFT
Ivabradine
N=3260
Placebo
N=3278
Bradycardia
10%
2.2%
Hypertension, blood
pressure increased
8.9%
7.8%
Atrial fibrillation
8.3%
6.6%
Phosphenes, visual
brightness
2.8%
0.5%
Luminous Phenomena (Phosphenes)
Phosphenes are phenomena described as a transiently
enhanced brightness in a limited area of the visual field, halos,
image decomposition (stroboscopic or kaleidoscopic effects),
colored bright lights, or multiple images (retinal persistency).
Phosphenes are usually triggered by sudden variations in
light intensity. Corlanor can cause phosphenes, thought to be
mediated through Corlanor’s effects on retinal photoreceptors
[see Clinical Pharmacology (12.1)]. Onset is generally within
the first 2 months of treatment, after which they may occur
repeatedly. Phosphenes were generally reported to be of mild to
moderate intensity and led to treatment discontinuation in < 1%
of patients; most resolved during or after treatment.
6.2 Postmarketing Experience
Because these reactions are reported voluntarily from a
population of uncertain size, it is not always possible to
estimate their frequency reliably or establish a causal
relationship to drug exposure.
The following adverse reactions have been identified during
post-approval use of Corlanor: syncope, hypotension,
angioedema, erythema, rash, pruritus, urticaria, vertigo,
diplopia, and visual impairment.
7. DRUG INTERACTIONS
7.1 Cytochrome P450-Based Interactions
Corlanor is primarily metabolized by CYP3A4. Concomitant
use of CYP3A4 inhibitors increases ivabradine plasma
concentrations, and use of CYP3A4 inducers decreases them.
Increased plasma concentrations may exacerbate bradycardia
and conduction disturbances.
The concomitant use of strong CYP3A4 inhibitors is
contraindicated [see Contraindications (4) and Clinical
Pharmacology (12.3)]. Examples of strong CYP3A4 inhibitors
include azole antifungals (e.g., itraconazole), macrolide
antibiotics (e.g., clarithromycin, telithromycin), HIV protease
inhibitors (e.g., nelfinavir), and nefazodone.
Avoid concomitant use of moderate CYP3A4 inhibitors when
using Corlanor. Examples of moderate CYP3A4 inhibitors
include diltiazem, verapamil, and grapefruit juice [see Warnings
and Precautions (5.3) and Clinical Pharmacology (12.3)].
Avoid concomitant use of CYP3A4 inducers when using
Corlanor. Examples of CYP3A4 inducers include St. John’s
wort, rifampicin, barbiturates, and phenytoin [see Clinical
Pharmacology (12.3)].
7.2 Negative Chronotropes
Most patients receiving Corlanor will also be treated with a betablocker. The risk of bradycardia increases with concomitant
administration of drugs that slow heart rate (e.g., digoxin,
amiodarone, beta-blockers). Monitor heart rate in patients
taking Corlanor with other negative chronotropes.
7.3 Pacemakers
Corlanor dosing is based on heart rate reduction, targeting
a heart rate of 50 to 60 beats per minute [see Dosage and
Administration (2)]. Patients with demand pacemakers set to
a rate ≥ 60 beats per minute cannot achieve a target heart rate
< 60 beats per minute, and these patients were excluded from
clinical trials [see Clinical Studies (14)]. The use of Corlanor is
not recommended in patients with demand pacemakers set to
rates ≥ 60 beats per minute.
8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on findings in animals, Corlanor may cause fetal harm
when administered to a pregnant woman. There are no
adequate and well-controlled studies of Corlanor in pregnant
women to inform any drug-associated risks. In animal
reproduction studies, oral administration of ivabradine to
pregnant rats during organogenesis at a dosage providing 1 to
3 times the human exposure (AUC0-24hr) at the MRHD resulted in
embryo-fetal toxicity and teratogenicity manifested as abnormal
shape of the heart, interventricular septal defect, and complex
anomalies of primary arteries. Increased postnatal mortality was
associated with these teratogenic effects in rats. In pregnant
rabbits, increased post-implantation loss was noted at an
exposure (AUC0-24hr) 5 times the human exposure at the MRHD.
Lower doses were not tested in rabbits. The background risk
of major birth defects for the indicated population is unknown.
The estimated background risk of major birth defects in the U.S.
general population is 2 to 4%, however, and the estimated risk
of miscarriage is 15 to 20% in clinically recognized pregnancies.
Advise a pregnant woman of the potential risk to the fetus.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Stroke volume and heart rate increase during pregnancy,
increasing cardiac output, especially during the first trimester.
Pregnant patients with left ventricular ejection fraction less
than 35% on maximally tolerated doses of beta-blockers may
be particularly heart-rate dependent for augmenting cardiac
output. Therefore, pregnant patients who are started on
Corlanor, especially during the first trimester, should be followed
closely for destabilization of their congestive heart failure that
could result from heart rate slowing.
Monitor pregnant women with chronic heart failure in 3rd
trimester of pregnancy for preterm birth.
Data
Animal Data
In pregnant rats, oral administration of ivabradine during
the period of organogenesis (gestation day 6-15) at doses of
2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and
teratogenic effects. Increased intrauterine and post-natal
mortality and cardiac malformations were observed at doses
≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD
based on AUC0-24hr). Teratogenic effects including interventricular
septal defect and complex anomalies of major arteries were
observed at doses ≥ 4.6 mg/kg/day (approximately 3 times the
human exposure at the MRHD based on AUC0-24hr).
In pregnant rabbits, oral administration of ivabradine during the
period of organogenesis (gestation day 6-18) at doses of 7, 14,
or 28 mg/kg/day resulted in fetal toxicity and teratogenicity.
Treatment with all doses ≥ 7 mg/kg/day (equivalent to the
human exposure at the MRHD based on AUC0-24hr) caused an
increase in post-implantation loss. At the high dose of 28 mg/kg/
day (approximately 15 times the human exposure at the MRHD
based on AUC0-24hr), reduced fetal and placental weights were
observed, and evidence of teratogenicity (ectrodactylia observed
in 2 of 148 fetuses from 2 of 18 litters) was demonstrated.
In the pre- and postnatal study, pregnant rats received
oral administration of ivabradine at doses of 2.5, 7, or
20 mg/kg/day from gestation day 6 to lactation day 20. Increased
postnatal mortality associated with cardiac teratogenic findings
was observed in the F1 pups delivered by dams treated at the
high dose (approximately 15 times the human exposure at the
MRHD based on AUC0-24hr).
8.2 Lactation
Risk Summary
There is no information regarding the presence of ivabradine in
human milk, the effects of ivabradine on the breastfed infant, or
the effects of the drug on milk production. Animal studies have
shown, however, that ivabradine is present in rat milk [see Data].
Because of the potential risk to breastfed infants from exposure
to Corlanor, breastfeeding is not recommended.
Data
Lactating rats received daily oral doses of [14C]-ivabradine
(7 mg/kg) on post-parturition days 10 to 14; milk and maternal
plasma were collected at 0.5 and 2.5 hours post-dose on
day 14. The ratios of total radioactivity associated with [14C]ivabradine or its metabolites in milk vs. plasma were 1.5 and
1.8, respectively, indicating that ivabradine is transferred to milk
after oral administration.
8.3 Females and Males of Reproductive Potential
Contraception
Females
Corlanor may cause fetal harm, based on animal data. Advise
females of reproductive potential to use effective contraception
during Corlanor treatment [see Use in Specific Populations (8.1)].
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been
established.
8.5 Geriatric Use
No pharmacokinetic differences have been observed in elderly
(≥ 65 years) or very elderly (≥ 75 years) patients compared to
the overall population. However, Corlanor has only been studied
in a limited number of patients ≥ 75 years of age.
8.6 Hepatic Impairment
No dose adjustment is required in patients with mild or moderate
hepatic impairment. Corlanor is contraindicated in patients with
severe hepatic impairment (Child-Pugh C) as it has not been studied
in this population and an increase in systemic exposure is anticipated
[see Contraindications (4) and Clinical Pharmacology (12.3)].
8.7 Renal Impairment
No dosage adjustment is required for patients with creatinine
clearance 15 to 60 mL/min. No data are available for patients
with creatinine clearance below 15 mL/min [see Clinical
Pharmacology (12.3)].
10. OVERDOSAGE
Overdose may lead to severe and prolonged bradycardia. In
the event of bradycardia with poor hemodynamic tolerance,
temporary cardiac pacing may be required. Supportive treatment,
including intravenous (IV) fluids, atropine, and intravenous betastimulating agents such as isoproterenol, may be considered.
This Brief Summary is based on the Corlanor® Prescribing
Information v1, 04/15
Corlanor® (ivabradine)
Manufactured for: Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
Patent: http://pat.amgen.com/Corlanor/
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-108642, v2 08/15
Download the
Mobile
Meeting Guide
9:15 AM
Dashboard
Mobile app available at
scientificsessions.org/mobile
My Schedule
Educational
Sessions
Faculty
Abstracts
Unofficial
Programs
Science &
Tech Hall
Maps
Get It
At Sessions
Sessions
Daily News
AHA
Newsroom
Science
News
Updates
Social
Networks
AHA EVENTS 2015
Use the above QR code to download the meeting guide app
now or search and download the app from the
Google play or App Store by searching “AHA Events”!
©2015, American Heart Association 8/15DS9611
BIGGER &
CUSTOMIZE your
experience with tracks.
Programming is divided into five main
categories: Basic, Clinical, Population, Special
Focus and Frontiers in Science. Each category
features a number of areas of interest to allow
you to focus your education in your specialty
or expand your knowledge in other areas. But
most important, you will be able to locate
what you need faster and more easily than
ever before.
Basic Science programming seeks to
provide state-of-the-art insights into the
underlying mechanisms of cardiovascular
development and disease. These insights
ultimately could lead to the development
of effective new interventions to better
diagnose, treat and prevent cardiovascular
disease.
Clinical Science programming aims to
provide access to the latest clinical and
Use the new areas of interest/tracks
scientific applications in the diagnosis,
to create a schedule that will make
medical management, prevention and treatment of
Scientific Sessions the right fit for you.
cardiovascular disease.
The Population Science programming provides
awareness of the most effective population-based
approaches to preventing cardiovascular diseases
and improving cardiovascular health across populations.
The Special Focus programming is comprised of various topics within cardiovascular
disease that are of continuing concern to clinicians, including the use of innovative tools and
technologies.
The Frontiers in Science meetings deliver one-day, science-focused gatherings that provide
an intimate setting for the free exchange of new ideas. Speakers present in a rapid-fire format,
encouraging discussion throughout the day. Because Frontiers in Science meetings focus on
pre-discovery/pre-publication topics, there is no recording of lectures or discussion; ideas are
not meant to be disseminated to the public.
See the box to the right for a complete list of the categories affiliated with each track.
6
BIG areas of interest/
tracks
BASIC
•Arteriosclerosis, Vascular Biology and
Development
• Cardiac Development, Structure and Function
• Genetics and Genomics
• Metabolism and Physiology
• Cellular Biology and Function
• Signaling Mechanisms and Drug Discovery
• Thrombosis, Immunity and Inflammation
CLINICAL
• Chronic and Acute Ischemic Heart Disease
• Arrhythmias and Electrophysiology
• Intervention and Surgery
• Heart Failure and Cardiomyopathies
•Hypertension
•Imaging
• Vascular Disease
•Stroke
• Nursing Clinical Symposium
POPULATION
• Prevention and Rehabilitation
• Obesity and Cardiometabolic Health
• Lifestyle Risk Factors
• Quality of Care and Outcomes
•Epidemiology
• Population Health Cohorts – Big Data
• Workplace Health
• Health Tech
SPECIAL FOCUS
• Nursing Science
• Clinical Trialists
• Lifelong Congenital Heart Disease and Heart
Health in the Young
• Resuscitation Science Symposium
FRONTIERS IN SCIENCE
•Arrhythmia Research Summit
• Vascular Disease
& BETTER
SESSIONS 2015 HIGHLIGHTS
LEARN in the
Health Tech sessions.
One fee.
FULL ACCESS.
Health Tech sessions explore the role of
technology in the treatment and prevention
of cardiovascular disease, examine ways to
drive innovation and collaboration in the
marketplace and, ultimately, drive toward a
health-technology road map with the goal of
improved outcomes.
Scientific Sessions registration now includes
access to more programming:
• Arrhythmia Research Summit
• Resuscitation Science Symposium
• Cardiovascular Nursing Clinical
Symposium
Health Tech sessions will address many topics,
from digital health solutions to implementation.
ATTEND Genomics Boot Camp.
The Science & Technology Hall will be home to
the new Simulation Zone.
LEARN in the
Simulation Zone.
At the Genomics Boot Camp, learn about genomics through case-based, active-learning activities.
Test your cardiac knowledge, skills and
critical thinking in AHA’s new hands-on,
interactive Simulation Zone.
PARTICIPATE in the 2015 Guidelines Instructor Conference.
Body Interact
Body Interact is an immersive training
platform that virtualizes acute and chronic
medical conditions.
Mechanical Circulatory Support Simulation
This area of the Simulation Zone provides a
hands-on opportunity to model critical scenarios
and observe hemodynamic consequences.
Attendees who have an interest in learning about
clinical genomics, especially non-scientists and clinical
practitioners (including physicians, nurses, pharmacists,
etc.) are welcome to attend this flipped classroom boot
camp. All Genomics Boot Camp participants must
complete the Basic Concepts in Genetics and Genomics
CME/CE activity on learn.heart.org prior to the event.
A certificate of completion must be presented for entry.
Don’t miss your opportunity to receive your required Guidelines Instructor update from the
AHA at the 2015 Guidelines Instructor Conference on Friday, Nov. 6, prior to Scientific
Sessions 2015.
Using a conference format, attendees will receive a comprehensive science update, and then add
sessions for each discipline. AHA science experts, volunteers and staff will outline what the new
guidelines mean for teaching lifesaving CPR and ECC courses. BLS, ACLS and PALS sessions
will be offered multiple times throughout the day of the conference. The Guidelines Instructor
Conference includes a fourth educational track for instructor development and enrichment.
7
BIG SCIENCE. BIG INNOVATION. BIG DISCOVERIES.
More than 17,000 cardiovascular healthcare
professionals attended Scientific Sessions last year,
including more than 6,000 international attendees
who came from more than 100 countries.
You asked. We listened. We delivered new offerings and enhanced favorites, giving you
more reasons than ever to attend Scientific Sessions 2015.
Scientific Sessions 2015 offers a unique opportunity to gather with colleagues
from around the world in an exciting educational and professional environment. The
scope and quality of the scientific exchange make Scientific Sessions the premier
cardiovascular research and educational meeting in the world.
BIG science
To extend your learning, you can connect
with the researchers involved in select trials
through the Meet the Trialists program.
Located in the Science & Technology Hall,
Meet the Trialists provides the opportunity
to get your questions answered in a casual
setting.
BIG clinical simulation
Presented in AHA’s newly formed
Simulation Zone, located in the Science
& Technology Hall, Body Interact is
EXPECT
Late-Breaking Clinical Trials bring you
face-to-face with leading experts in the
cardiovascular field as they unveil the latest
breakthroughs in clinical science. These
innovative presentations likely will have a
significant impact on your clinic practice,
making them one of the must-see forums
at Scientific Sessions. The Clinical Science
Special Report sessions highlight trial
updates, registries and important clinical
science in a variety of specialties.
THINGS
8
Learn from the cardiovascular community’s
leading presenters at Scientific Sessions 2015.
an immersive training platform that
virtualizes acute and chronic medical
conditions. Experts will facilitate realistic
user experiences with a life-like virtual
patient, complete with dynamic monitoring,
dialoguing, test orders, scans, drugs,
intervention options and performance
debriefing.
The Simulation Zone is also where
you’ll find Mechanical Circulatory Support
Simulation. The field of mechanical
circulatory support provides longer and
improved quality of life for patients with
end stage heart failure. As innovation in
this field impacts an increasing number of
patients, new diagnostic dilemmas challenge
the clinician. The Mechanical Circulatory
Support Simulation — led by industry
experts — provides a hands-on opportunity
to model critical scenarios and observe
hemodynamic consequences. A total artificial
heart mock circulatory loop paired with
both axial and centrifugal continuous flow
devices will test scenarios such as inadequate
preload/afterload conditions, right heart
failure and device obstruction.
BIG TECHNOLOGY. BIG NETWORKING. IT’S ALL HERE.
BIG innovation
Schedule time to explore the Science &
Technology Hall, where you’ll discover
the latest in technology, services and
products. You will find areas dedicated to
the tools and resources for your business
and practice. Check out the Cardiovascular
Expert Theaters to find specific products
and therapeutic treatments, and visit the
Emerging Science & Technology Showcase
to see the latest technologies in prevention,
diagnosis and treatment of cardiovascular
disease.
BIG technology
If you aren’t following Scientific Sessions
2015 on your smartphone or mobile device,
you’re missing out.
Use the Mobile Meeting Guide app to
get instant access to educational sessions,
ePosters, abstracts, faculty, event information,
hotels, schedule planning and maps. Ask
questions and engage with big-name speakers
in our most popular sessions live by using
the Digital Moderators component. Listen
The Mobile Meeting Guide offers instant access to educational sessions, abstracts and more.
BIG events
Conference Notes
Available in more sessions this
year, Conference Notes is an app
which allows you to follow along
with presentations in real time,
bookmark important slides to
revisit later, and add notes and
sketches directly on your screen.
Conference Notes is available
on iPad or through your internet
browser for laptop viewing. Please
bring your own iPad or laptop to
experience Conference Notes
during Sessions 2015. The app is
provided by AstraZeneca.
Visit with the many exhibitors in the Science
& Technology Hall.
to live stream audio from all the educational
sessions. Navigate the meeting through
the interactive map, get information on all
the Science & Technology Hall exhibitors,
and expand your professional network.
Additionally, with easy access to your
Scientific Sessions photos, you can quickly
share your pictures on social networks.
(Follow us on social media using #AHA15.)
Never stop learning. In addition to the
hundreds of presentations and educational
opportunities at Scientific Sessions, you
also have access to Unofficial Satellite
Events — independently organized
scientific and educational activities offered
and/or accredited by various sponsoring
organizations. These events will be held
during Scientific Sessions 2015 before and
after official programming, giving you an
opportunity for additional learning and
networking.
BIG information
HeartQuarters, located in Booth 859 in
the Science & Technology Hall, is your
one-stop shop for all things American Heart
Association. Here you can join or renew
AHA/ASA Professional Membership, learn
about councils, browse various scientific
publications, explore online professional
education activities and attend events in the
theater.
9
you to give your feet a break by trading your
business shoes for comfortable walking
shoes. To ignite your competitive side,
we’ll host the Annual Sessions Walking
Challenge, which will track your daily steps.
The program will feed all numbers into a
leaderboard so users can monitor their daily
progress and see how they compare to the
leading walkers at Sessions.
PACKING LIST
When packing your bags to come to
Scientific Sessions 2015, remember to bring
these items:
❏ iPad or laptop — so you can participate
in Conference Notes
❏ Sneakers — for Wear Sneakers Day
❏ Red attire — so you can support Wear
BIG opportunities
Walking is a part of Scientific Sessions. Turn
it into something fun by participating in the
Walking Challenge.
Come see our new layout featuring the
Collaboration Station and Shop Heart, as well
as Science, Patient and Consumer programs.
Our theater will hold hourly presentations.
Check out the interactive global map which
will allow you to see your colleagues from
around that world that are attending Scientific
Sessions.
BIG fitness
Just because you’re traveling doesn’t mean
you have to kick your daily exercise routine
to the curb. AHA has planned several
activities for you. Wear Your Sneakers Day
will be Tuesday, Nov. 10, when we invite
Early career members are invited to engage
with senior investigators at the Early Career
Day on Saturday, Nov. 7. The day features an
opening general session, a networking lunch
and specialty breakout sessions.
At the Early Career Engagement Lounge,
you can meet the experts, learn how AHA
membership can help you achieve your
goals, network with peers and see what other
attendees are saying on our social media sites.
BIG discoveries
Don’t miss the cutting-edge original research
presented through Posters and ePosters that
are displayed in the Poster Hall. You can
view these at personal workstations or on
your smartphone. You also are encouraged to
go online and communicate with presenters
via email.
Posters presenters will be able to network
with Poster Professors — the top researchers
in a presenter’s field of interest — who will
make rounds to welcome and network with
Red for Women Day
❏ Fitness tracker — to track all your steps
❏ Business cards — for networking
poster presenters for increased interaction
and robust discussion.
The Best of AHA Specialty Conferences
Poster Session features the top 10 percent
of abstracts presented at the 2015 specialty
conferences. Meet these poster presenters
from 9:30 to 11 a.m., Monday, Nov. 9.
An addition to our Poster program is the
Basic Science Reception, which recognizes
the best of basic science abstracts, as well as
late-breaking basic science abstracts. It will
be held from 5 to 7 p.m., Monday, Nov. 9.
Check out the Case Theaters: Learning
at the Movies, presentations that showcase
technical aspects and management
of procedures performed in patients,
accompanied by a panel of experts for intense
discussion. The Case Theaters are 45-minute
live presentations of case presentations
by international experts in challenging
and controversial situations in structural
heart disorders, cardiac surgery, vascular
intervention and advanced heart failure.
BIG networking
Meet, network and share ideas with colleagues at Scientific Sessions 2015.
10
Scientific Sessions attracts nearly 17,000
attendees, with a global presence from more
than 100 countries, making it the perfect
place to expand your network and share
your knowledge on cardiovascular diseases
and stroke with like-minded professionals.
Several networking opportunities are
available during the week, including Meet
the Trialists, Case Theaters: Learning at the
Movies, EP Central, Simulation Zone, WiFi/
Charging Lounges, Early Career Lounge,
council dinners, as well as the Members
Circle and AHA Fellows Lounge.
Heart Disease and Stroke
Statistics—2015 Update
Your only source for verified data on US cardiovascular health
Rates of death attributable to cardiovascular diseases
(CVD) have declined, yet the burden of disease remains
high. Based on 2011 data:
• The overall rate of death attributable to CVD was 229.6 per 100,000.
• More than 2150 Americans die of CVD each day, an average of 1 death
every 40 seconds.
• Stroke accounted for ≈1 of every 20 deaths in the United States.
Prevalence and control of traditional risk factors
remains an issue for many Americans:
• 32.6% of US adults have hypertension. That’s 80 million adults.
• An estimated 30.9 million adults have total serum cholesterol levels
≥240 mg/dL.
• Among adults in the United States, 1 in 5 men and 1 in 6 women are
current smokers.
Presence of ideal cardiovascular health is age, sex, and
race related:
• Younger adults are more likely to meet greater numbers of ideal metrics than are older
adults. More than 60% of Americans >60 years of age have ≤2 metrics at ideal levels.
At any age, women tend to have more metrics at ideal levels than do men.
• Blacks and Mexican Americans tend to have fewer metrics at ideal levels than whites
or other races. Approximately 6 in 10 white adults and 7 in 10 black or Mexican
American adults have no more than 3 of 7 metrics at ideal levels.
Visit circ.ahajournals.org/site/StatUpdate to link to the full-text article.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB,
McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW,
Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation.
2015;131:e29–e322. doi: 10.1161/CIR.0000000000000152.
5-Q001
SCIENTIFIC SESSIONS
Nov
7
Saturday
7:00
8:00
9:00
Sunday
8
11:00
12:00
1:00
Early Career Day
Includes a general session, specialty breakouts (including the Peripheral Vascular Disease FIT Workshop)
and a reception for all.
Invited Sessions
Nov
10:00
Lunch Break
Science & Technology Exhibit Hall
Opening
Session
Poster Sessions
Nov
10
Nov
11
Wear Sneakers Day
9
Wednesday
Nov
Wear Red Day
Invited Sessions
and Invited Sessions
Oral Abstracts
Oral Abstracts
Lunch Break
Poster Sessions
Invited Sessions
Oral Abstracts
Oral Abstracts
Lunch Break
Poster Sessions
Invited Sessions
Don’t Miss Out on These
Other Key Events
Invited Sessions and
Sa
Su
M
Resuscitation Science Symposium
Saturday-Monday Nov. 7-9
M
Frontiers in Science:
Arrhythmia Research Summit
Monday Nov. 9
12
WEEK AT-A-GLANCE
2:00
3:00
4:00
5:00
6:00
7:00
Invited Sessions
Oral Abstracts
Oral Abstracts
Invited Sessions
Invited Sessions
Invited Sessions
Oral Abstracts
Oral Abstracts
Oral Abstracts
Invited Sessions
Invited Sessions
Invited Sessions
Oral Abstracts
Oral Abstracts
Oral Abstracts
Council Dinners
Rosen Center
Orlando, Florida
M
Frontiers in Science:
Vascular Disease
M
Tu
Health Tech
Monday Nov. 9
Monday Nov. 9
M
Tu
Clinical Nursing Symposium
Monday-Tuesday Nov. 9-10
Workplace Health
Monday Nov. 9
Tu
Clinical Trialists
Tuesday Nov. 10
13
ADVANCE PROGRAM AND FACULTY
LATE-BREAKING CLINICAL TRIALS AND
LATE-BREAKING
CLINICAL TRIALS
SUNDAY, NOV. 8
Oral sGC Stimulator Vericiguat in Patients With
Worsening Chronic Heart Failure and Reduced
Ejection Fraction — The SOluble guanylate
Cyclase stimulatoR in heArT failurE patientS with
REDUCED EF (SOCRATES-REDUCED) Study
SOCRATES-REDUCED: Phase II dose finding
LBCT.01, 3:45-5 p.m.
trial of the once daily sGC stimulator vericiguat
Failure is Not an Option:
New Drugs and Systems of Care
added to standard therapy in patients with
worsening chronic HF and reduced ejection
fraction over 12 weeks.
A Randomized Trial of Liraglutide for
High-Risk Heart Failure Patients With
Reduced Ejection Fraction
controlled clinical trial of treatment with
Remote Patient Management After Discharge
of Hospitalized Heart Failure Patients:
The Better Effectiveness After Transition —
Heart Failure Study
liraglutide versus placebo for six months in high-
BEAT-HF: The Better Effectiveness After
risk HF patients with reduced ejection fraction
Transition — Heart Failure (BEAT-HF) study is a
(LVEF ≤ 40 percent) and recent hospitalization.
comparative effectiveness randomized control
FIGHT: A randomized, double-blinded, placebo-
trial that evaluated a remote patient management
Nitrate’s Effect on Activity Tolerance
in Heart Failure With Preserved Ejection
Fraction (NEAT-HFpEF)
NEAT-HFpEF: This trial was designed to evaluate
MONDAY, NOV. 9
care transition approach to reduce readmissions
for 1,404 hospitalized heart failure patients aged
LBCT.02, 10:45-11:55 a.m.
50 years and over.
Decreasing the Global Burden
of Disease: Breakthroughs in Prevention
the effect of isosorbide mononitrate on activity
tolerance in heart failure with preserved ejection
fraction.
The Efficacy and Safety of Varenicline, a
Selective Alpha4beta2 Nicotinic Receptor Partial
Agonist, for Smoking Cessation in Patients
Hospitalized With Acute Coronary Syndrome:
A Randomized Controlled Trial
E VITA: This trial was designed to evaluate the
efficacy and safety of varenicline for smoking
cessation in patients hospitalized with acute
coronary syndrome.
14
CLINICAL SCIENCE SPECIAL REPORTS
Clinical Trial of a Mobile Health Intervention
for Simultaneous Versus Sequential Diet and
Activity Change
Clinical Outcomes of Intravascular Ultrasound
Guided Everolimus-Eluting Stents Implantation
in Long Coronary Lesions
MBC2: Make Better Choices 2 is a mobile health
IVUSXPL: During the PCI procedure,
trial designed to determine whether targeting
intravascular ultrasound (IVUS) is a useful tool for
diet and activity risk behaviors simultaneously or
providing information on pre-intervention lesion
sequentially maximized healthy lifestyle change.
characteristics and post-intervention optimal
stent implantation. Although recent guidelines
The Effect of Disclosing Genomic Risk of
Coronary Heart Disease on Low-Density
Lipoprotein Cholesterol Levels: The Myocardial
Infarction Genes (MI-GENES) Study
recommend the use of IVUS to optimize stent
MI-GENES: Individuals who received a genetic
remains uncertain because of the limited number
risk score for coronary heart disease had
of properly powered randomized studies. In
significantly lower LDL-C levels than participants
addition, although first-generation DESs were
who received a conventional risk score.
commonly used in most studies for investigating
Knowledge of genetic risk of coronary heart
the IVUS-guided DES implantation, second-
disease may have clinical utility.
generation DESs are exclusively used for PCI
implantation for select patients, the impact
of IVUS-guided drug-eluting stent (DES)
implantation on improved clinical outcomes
in current clinical practice, and determining
Empagliflozin and Cardiovascular Outcomes
in Patients with Type 2 Diabetes Mellitus at
High Cardiovascular Risk
the clinical usefulness of IVUS-guidance in the
EMPA-REG OUTCOME: This trial is the
clinical benefit of IVUS-guidance in second-
frontrunner and first-in-class CV outcome trial
generation DES implantation in an adequately
in type 2 diabetes involving an SGLT-2 inhibitor
powered randomized clinical trial.
implantation of these DESs is also required. The
current study is the first demonstration of the
Impact of a Comprehensive Lifestyle PeerGroup-Based Intervention on Cardiovascular
Risk Factors: A Randomized Controlled Trial
(empagliflozin).
Fifty-Fifty Program: The aim of the Fifty-Fifty
TUESDAY, NOV. 10
PEGASUS-TIMI 54: This was a trial designed
multicenter community-based comprehensive
LBCT.03, 10:45 a.m.-12:10 p.m.
with two dosing strategies for chronic secondary
lifestyle intervention for the self-control of
ACS and PCI: The Continuum of Care
prevention.
Program was to evaluate the impact of a
Long-Term Tolerability of Ticagrelor in the
PEGASUS-TIMI 54 Trial
to evaluate the efficacy and safety of ticagrelor
cardiovascular risk factor through peer-group
dynamics.
Providing Rapid Out of Hospital Acute
Cardiovascular Treatment (PROACT-4)
PROACT-4: This trial was designed to test the
addition of point-of-care troponin testing in the
ambulance for patients with chest pain. Funded
by the Heart and Stroke Foundation Canada.
While every effort is made to ensure the accuracy of data within this
publication, the publisher cannot be held responsible for errors or
omissions. Data current as of Aug. 25, 2015.
15
Individualizing Treatment Duration of Dual
Antiplatelet Therapy After Percutaneous
Coronary Intervention: An Analysis of the
DAPT Study
DAPT: The Dual Antiplatelet Therapy Study
Prevention of Cardiac Dysfunction During
Adjuvant Breast Cancer Therapy (PRADA):
Primary Results of a Randomized, 2 x 2
Factorial, Placebo-Controlled, Double-Blind
Clinical Trial
was an international, multicenter, double-
PRADA: This randomized, placebo-controlled,
blind, randomized trial that investigated the
double-blind trial assessed the effect of the
ALN-PCSsc, an RNAi Investigational Agent
That Inhibits PCSK9 With Potential for Effective
Quarterly or Possibly Bi-Annual Dosing: Results
of Single-Blind, Placebo-Controlled, Phase 1
Single-Ascending Dose (SAD), and Multi-Dose
(MD) Trial in Adults With Elevated LDL-C, on and
off Statins
benefits and risks of 30 versus 12 months of
beta blocker metoprolol and the angiotensin
ALN-PCSsc: An RNAi investigational agent
dual antiplatelet therapy in patients undergoing
receptor blocker candesartan as preventive
that inhibits PCSK9 with potential for effective
percutaneous coronary intervention with drug-
cardioprotective therapy in women treated with
quarterly or possibly bi-annual dosing.
eluting or bare metal stents.
an anthracycline-containing early adjuvant breast
cancer regimen with or without trastuzumab and
Angina and Quality of Life Following PCI
With Incomplete Revascularization: Results
From the Ranolazine for Incomplete Vessel
Revascularization (RIVER-PCI) Trial
radiation.
CLINICAL SCIENCE
SPECIAL REPORTS
placebo, and followed them for ischemia-
ANNEXA-R Part 2: A Phase 3 Randomized,
Double-Blind, Placebo-Controlled Trial
Demonstrating Sustained Reversal of
Rivaroxaban-Induced Anticoagulation in Older
Subjects by Andexanet Alfa (PRT064445), a
Universal Antidote for Factor XA (FXA) Inhibitors
driven hospitalization or revascularization and
ANNEXA-R: Andexanet Alfa a Novel Antidote
CS.01, 9-10:15 a.m.
patient-reported angina and quality of life during
to the Anticoagulant Effects of fXA Inhibitors –
follow-up.
Rivaroxaban: ANNEXATM is a four-part, Phase
Novel Findings From Next
Generation Registries
RIVER-PCI: This trial randomized patients
with a history of angina and incomplete
revascularization after PCI to ranolazine or
MONDAY, NOV. 9
3, double-blind, placebo-controlled program
WEDNESDAY, NOV. 11
subjects treated with rivaroxaban or apixaban;
LBCT.04, 10:45 a.m.-12:15 p.m.
AnXa followed by a two-hour continuous infusion
Increased Incidence of Infective Endocarditis
After the 2009 European Society of Cardiology
Guideline Update: A Nationwide Study in the
Netherlands
Novel Therapies for Common Problems
will be presented.
This is the first nationwide study evaluating the
One Year Follow-up Results From
AUGMENT-HF: A Multicenter Randomized
Controlled Clinical Trial of the Efficacy of Left
Ventricular Augmentation With Algisyl-LVR in the
Treatment of Heart Failure
Prevention of Acute Kidney Injury by Nitric
Oxide During and After Prolonged
Cardiopulmonary Bypass. A Double Blind
Randomized Controlled Trial
guidelines on the prevention, diagnosis and
NITRIC: Nitric Oxide was delivered during and
One year follow-up results from AUGMENT-HF:
after prolonged cardio-pulmonary bypass to
A multicenter, randomized, controlled clinical
prevent acute kidney injury caused by plasma-
trial testing a novel heart failure therapy as a
Hb induced NO scavenging.
Examining Prevailing Genotype-Phenotype
Correlations in Hypertrophic Cardiomyopathy:
Findings From the Sarcomeric Human
Cardiomyopathy Registry (SHaRe)
comprised of two studies of AnXa in older
ANNEXA-R Part 2 which investigated a bolus of
updated 2009 European Society of Cardiology
The-First-in-Man Randomized Trial of a ß3adrenoceptor Agonist in Chronic Heart Failure —
the BEAT-HF Trial
recommendations.
SHARE: The Sarcomeric Human Cardiomyopathy
potentially effective treatment for patients with
advanced HF.
treatment of infective endocarditis prophylaxis
A Randomized, Placebo Controlled Trial of Late
Na Channel Inhibition (ranolazine) in Coronary
Microvascular Dysfunction (CMD): Impact on
Angina and Myocardial Ischemia
Registry (SHaRe) was established to amass
RWISE: We conducted a randomized, double-
robust large-scale, longitudinal genotype,
phenotype and outcomes data for HCM.
BEAT-HF: This trial was designed to evaluate the
blinded, placebo-controlled, crossover trial of
effect on heart pump function and safety of a
oral ranolazine 500-1,000 mg twice daily for two
beta 3 receptor agonist in patients with chronic
weeks in women and men with symptoms and
The Impact of the Appropriate Use Criteria
on Patient Selection and Appropriateness
of Percutaneous Coronary Intervention —
Findings From the NCDR-CathPCI Registry
heart failure.
signs of myocardial ischemia, no obstructive
Assessing the impact of the appropriate use
CAD and abnormal CFR or abnormal myocardial
criteria on appropriateness of PCI between July
perfusion reserve index (MPRI) on CMRI.
2009 and December 2014.
16
Clopidogrel on Top of Aspirin for the Prevention
of New-Onset Migraine Headache Attacks
Following Transcatheter Closure of Atrial Septal
Defects: A Prospective, Randomized, Double
Blind Trial (CANOA)
CANOA: This trial was designed to evaluate the
efficacy of clopidogrel on top of aspirin for the
prevention of migraine attacks following atrial
septal defect closure.
MONDAY, NOV. 9
CS.02. 3:45-5:05 p.m.
Cutting-Edge Technologies in EP
Cardiac Resynchronization Therapy Is
Detrimental in Patients With QRS Duration
Greater Than 180ms and Right Bundle
Branch Block Morphology: Analysis From the
Medicare ICD Registry
Cardiac resynchronization therapy is detrimental
in patients with QRS duration greater than 180ms
and right bundle branch block morphology.
Four Late-Breaking Clinical Trials sessions and three Clinical Science Special Reports sessions will
be presented during Scientific Sessions 2015.
Analysis from the Medicare ICD registry.
Miniaturized Transcatheter Delivered
Cardiac Pacing: Primary Results of a Worldwide
Clinical Trial
TUESDAY, NOV. 10
The purpose of this clinical study was to
Managing Risk Factors
for CAD — Clinical Trial Updates
evaluate the safety and efficacy of the Micra
CS.03, 3:45-5:03 p.m.
Long-Term Cardiovascular Effects of 4.9 Years
of Intensive Blood Pressure Control in Type
2 Diabetes Mellitus: The Action to Control
Cardiovascular Risk in Diabetes Follow-on Blood
Pressure Study
ACCORDION Follow-on BP Study: This study
Transcatheter Pacing System and to assess
long-term performance.
Cholesterol Treatment Targets and Clinical
Outcomes: A JUPITER Trial Update
assessed the long-term (10-year) effect of 4.9
A Randomized Controlled Trial of a Video
Decision Support Tool to Depict Goals of Care
and Resuscitation Options for Patients With
Advanced Heart Failure
JUPITER: This analysis of the completed
(<140 mm Hg) systolic blood pressure lowering
JUPITER trial addresses whether or not on-
on the incidence of cardiovascular events or
treatment target levels of LDLC, non-HDLC
death in 4733 people with type 2 diabetes and
and apo B are relevant for event reductions
high cardiovascular risk.
This trial is a randomized controlled trial evaluating
attributable to statin therapy, an issue relevant
the impact of a goals-of-care video decision
for current guidelines.
support tool on decisions regarding CPR/
Peri-Procedural Safety of Left Atrial Appendage
Occlusion With the WATCHMAN Device.
Preliminary Data From the EWOLUTION Registry
Relationship Between High-Density Lipoprotein
Cholesterol and Cardiovascular and NonCardiovascular Mortality: A Population-Based Study
of More Than 630,000 Individuals Without Prior
Cardiovascular Conditions in Ontario, Canada
EWOLUTION: This prospective registry aimed to
Canheart (CArdiovascular HEalth in Ambulatory
obtain data on real world efficacy and safety of
Care Research Team): A team that leverages big
Watchman LAA occlusion.
data to improve the outpatient care provided to
intubation for patients with advanced heart failure.
years of intensive (<120 mm Hg) versus standard
Revascularization in Patients With Diabetes
and Multivessel Coronary Artery Disease:
A Population-Based Evaluation of Outcomes
Results from a real-world experience in
revascularization of patients with diabetes
and multivessel coronary disease from British
Columbia.
patients with cardiovascular risk factors and/or
chronic conditions.
17
PROFESSION A L M E M B E R S HI P
my.americanheart.org
Whether you are an early career member looking to learn and grow in your specialty,
or a FAHA looking to broaden your leadership opportunities, there are unique AHA
Professional Membership benefits that are tailored to you and your career stage.
P RO FE SSIONAL ME MB E R SHIP BENEFITS INCLUDE:*
• Up to $400 in savings on Scientific Sessions 2015 registration — plus registration
savings at AHA’s other scientific conferences.
• Complimentary access to Sessions OnDemand.TM
• Benefits that extend beyond science so you can contribute to AHA’s mission
of building healthier lives, free of cardiovascular diseases and stroke.
• Unprecedented access to research and clinical information across multiple specialties.
• Be a part of our AHA Professional Online Network — connect with peers and
leaders in your specialty.
• The research grant application fee is waived for members. You can apply at
my.americanheart.org/research.
• Online access to AHA Scientific journals (full text).
We’re proud that our membership includes more than 7,300 international professionals,
in more than 128 countries outside the United States, dedicated to our mission of
building healthier lives, free of cardiovascular diseases and stroke. Become part of a
huge network making a global impact on the fight against cardiovascular diseases
and stroke. We couldn’t fight this fight without you.
Visit our staff at HeartQuarters in the
Science & Technology Hall, Booth 859
* Benefits depend on membership tier.
to learn more about the benefits of professional membership
and join our network of almost 33,000 members today.
SCIENTIFIC PROGRAMMING
ABSTRACT ORAL SESSIONS
Keith A. Fox, BSC, MB, ChB, FESC, FRCP
Edinburgh, United Kingdom
Got questions? Get answers during these
sessions, which allow you to interact with
the presenter and generate meaningful
discussion.
Abstract Oral Sessions will have 15
minutes allotted for each abstract presenter
(10 minutes presentation followed by five
minutes of questions and answers).
Early Career Investigator Award Sessions
will recognize promising and outstanding
investigators in the early stages of their
careers, stimulate continued interest in basic
or clinical research and help early career
investigators participate in AHA meetings.
Featured Research Sessions will offer
state-of-the-science lectures on compelling
areas of research. Speakers in this category
have not only made outstanding contributions
to the field, but are also talented teachers and
communicators.
Named Lectures/Council-sponsored
lectures are presented throughout the
meeting in honor of scientists and AHA
volunteers who have made outstanding
contributions to the field and the American
Heart Association.
Lasker Laureate Lecture
ABSTRACT POSTER SESSIONS
Alain Carpentier, MD, PhD
Paris
Don’t pass up the Poster Sessions in Poster
Hall. You can view them Sunday, Nov.
8 through Tuesday, Nov. 10. Want more
information? Meet with the authors from
9 to 10:15 a.m., 2 to 3:15 p.m. or 5:30 to 6:45
p.m., Sunday, Nov. 8, through Tuesday, Nov.
10, with Poster Professors making rounds to
meet authors for increased interaction and
robust discussion.
SPECIAL LECTURES
Presidential Address
Mark A. Creager, MD, FAHA
Lebanon, New Hampshire
Lewis A. Conner Memorial Lecture
Andrew Conrad, PhD
San Francisco
Paul Dudley White International
Lecture
Distinguished Scientist Lecture
Christine Seidman, MD, FAHA
Boston
Keynote Address by the Director
of the National Institutes of Health
Francis S. Collins, MD, PhD
Bethesda, Maryland
20
EARLY CAREER PROGRAMMING
SATURDAY, NOV. 7
9 a.m.-Noon
General Session
11:45 a.m.-12:45 p.m.
Complimentary lunch sponsored by AHA/
ASA membership
1-5 p.m.
Specialty Science Breakouts (including the
PVD FIT Workshop, 9 a.m.-5 p.m.)
5-6:30 p.m. Reception
CLINICAL SCIENCE
SPECIAL REPORTS
See pages 16-17 for details.
MONDAY, NOV. 9
Novel Findings From Next
Generation Registries CS.01
Cutting-Edge Technologies in EP CS.02
TUESDAY, NOV. 10
Managing Risk Factors for CAD —
Clinical Trial Updates CS.03
More than 800 sessions will be presented at
Scientific Sessions 2015.
LATE-BREAKING CLINICAL TRIALS
See pages 14-16 for details.
BIG IDEAS: 30 AREAS OF INTEREST/TRACKS
SUNDAY, NOV. 8
Basic
Population
Failure is Not an Option: New Drugs and
Systems of Care LBCT.01
Arteriosclerosis, Vascular Biology and Development
Cardiac Development, Structure and Function
Genetics and Genomics
Metabolism and Physiology
Cellular Biology and Function
Signaling Mechanisms and Drug Discovery
Thrombosis, Immunity and Inflammation
Prevention and Rehabilitation
Obesity and Cardiometabolic Health
Lifestyle Risk Factors and Behavior Change
Quality of Care and Outcomes
Epidemiology
Population Health Cohorts - Big Data
Workplace Health
Health Tech
MONDAY, NOV. 9
Decreasing the Global Burden of Disease:
Breakthroughs in Prevention LBCT.02
TUESDAY, NOV. 10
ACS and PCI: The Continuum of Care LBCT.03
WEDNESDAY, NOV. 11
Novel Therapies for Common Problems
LBCT.04
MEET THE TRIALISTS
MONDAY, NOV. 9
Clinical
Chronic and Acute Ischemic Heart Disease
Arrythmias and Electrophysiology
Intervention and Surgery
Heart Failure and Cardiomyopathies
Hypertension
Imaging
Vascular Disease
Stroke
Nursing Clinical Symposium
Special Focus
Nursing Science
Clinical Trialists
Lifelong CHD and Heart Health in the Young
Resuscitation Science Symposium
Frontiers in Science
Arrhythmia Research Summit
Vascular Disease
TUESDAY, NOV. 10
OPENING SESSION
WEDNESDAY, NOV. 11
SUNDAY, NOV. 8
Navigating the Complex Landscape of Heart
Failure PS.09
Opening Session OPS.01
PLENARY SESSIONS
SUNDAY, NOV. 8
Affordable Care Act Effects on Patients,
Clinicians and Scientists PS.01
MONDAY, NOV. 9
Endovascular Stroke Therapy Trials Update
2015 PS.05
Therapeutic Decisions in Non-ST Elevation
Myocardial Infarction PS.02
What Is the Role of Nonstatins in the Statin
Era? PS.03
Clinical Care Across the Age Continuum:
Creating Bridges to Improve Care and
Outcomes from Age 0-100 SS.11
Genetics in Clinical Practice SS.09
SPECIAL SESSIONS
Hypertension and Diabetes Mellitus: The
Foundation of Both Heart and Kidney Disease
SUNDAY, NOV. 8
SS.07
Advances in Structural Heart Disease
Interventions for the Clinician SS.01
Precision Medicine SS.08
MONDAY, NOV. 9
Addressing Atherosclerotic Risk in the
Under-40 Crowd: Gaps in Guidelines and
Gaps in Care SS.02
Cardiovascular Disease Health Disparities
in African-Americans, Hispanics and Rural
Populations SS.06
Distinguished Scientist Lecture SS.10
WEDNESDAY, NOV. 11
Joint Session AHA/WHO — 10 Years to WHO
2025 Goals: Where Do We Stand? How Far to
Go? SS.13
Updated Implementation of Multimodality
Imaging Based on Guidelines (Joint Session
with European Society of Cardiology) SS.12
Artificial Hearts: Lasker Awardee Lecture
SS.04
TUESDAY, NOV. 10
Atrial Fibrillation: State of the Art and Future
Direction PS.06
Improving Outcomes in Women’s
Cardiovascular Health PS.08
Plaque Vulnerability, Imaging and
Cardiovascular Risk: The Bedside Meets the
Bench PS.07
Resuscitation Guidelines 2015 PS.04
Sex-Based Differences in Cardiovascular
Disease SS.03
TO BE CONTINUED: CME/CE
Solving the Myocyte Loss Problem in Heart
Failure SS.05
Physicians, physician assistants,
nurses and pharmacists may apply
for continuing medical education
accreditation. There is no fee for CME/
CE credits. For complete CME/CE
accreditation information for Scientific
Sessions 2015, visit learn.heart.org.
TUESDAY, NOV. 10
Best of Other Cardiovascular Meetings
(Domestic and International) SS.14
21
SPEAKERS
MEET THE 2015 FACULTY
A
Keith D. Aaronson
Antonio Abbate
Brian Abbott
J. Dawn Abbott
Maha Abdellatif
Jun-Ichi Abe
Willie Mae Abel
Benjamin S. Abella
Victor Aboyans
William T. Abraham
Cathie Abrahamsen
Dominic Abrams
Hugues Abriel
Mazen Abu-fadel
Michael A. Acker
Michael J. Ackerman
Jasimuddin Ahamed
Tariq Ahmad
Xun Ai
Ernesto A. Aiello
Elena Aikawa
Masanori Aikawa
Teiji Akagi
Fadi G. Akar
Shahab A. Akhter
Sana Al Khatib
Christine Albert
Nancy Albert
Ryan Aleong
22
Sheila Alexander
Thomas Alexander
Larry A. Allen
Norrina B. Allen
Matthew A. Allison
Christopher Almond
Adah Almutairi
Joseph S. Alpert
Ahmed AlSayed
Salomon Amar
Amrut Ambardekar
Inder S. Anand
CIndy Anderson
Jeffrey Anderson
Mark E. Anderson
Dean Andropoulos
Stefan D. Anker
Elad Anter
Elliott Antman
Charalambos
Antoniades
Ani Anyanwu
Lawrence J. Appel
Susan E. Appt
Christina Aquilante
Jayashin Aragam
Jesus A. Araujo
Stephen Archer
Amer K. Ardati
Reza Ardehali
Ross Arena
Hermenegild Arevalo
Luisa I. Arispe
Aimee Armstrong
Paul W. Armstrong
Donna Arnett
Suzanne V. Arnold
Herbert Aronow
Pankaj Arora
Rakesh Arora
Kent Arrell
Nancy Artinian
Takayuki Asahara
Alfred A. AsanteKorang
Susan Ashcraft
Euan Ashley
Houman Ashrafian
Stella Aslibekyan
Dianne L. Atkins
Tom Aufderheide
Eric Austin
Alberto Avolio
B
Andrea Baccarelli
Emile Bacha
Carl L. Backer
Leonard L. Bailey
Steven R. Bailey
Noel C. Bairey-Merz
Tamilyn Bakas
Andrew Baker
Gary J. Balady
Ravi C. Balijepalli
Christie M. Ballantyne
Jean Luc Balligand
Sripal Bangalore
Gust H. Bardy
Susan A. Barnason
Geoffrey Barnes
Tracie A. Barnett
Taura L. Barr
Gregory W. Barsness
Philip Barter
Jerry Bartholomew
John Bass
Cristina Basso
Eric R. Bates
Mary E. Bauman
Iris Baumgartner
William A.
Baumgartner
Anthony Bavry
Jeroen Bax
Rob Beanlands
Lance Becker
Theresa Beckie
Joshua A. Beckman
Elijah R. Behr
Amber Beitelshees
John F. Beltrame
Frank Bengel
Emelia Benjamin
Martin Bennett
Rhonda Bentley-Lewis
Omer Berenfeld
Peter Berger
Jarett D. Berry
Donald M. Bers
Stefan Bertog
Luc Bertrand
Olivier Bertrand
Charles I. Berul
Hiram G. Bezerra
Aruni Bhatnagar
Deepak Bhatt
Kirsten BibbinsDomingo
Charles Billington
Joyce Bischoff
Gianluigi Bisleri
Malenka M. Bissell
Vera Bittner
Steven Blair
Philipp Blanke
Ron Blankstein
Burns Blaxall
Nico A. Blom
Gerald S. Bloomfield
David A. Bluemke
Elizabeth Blume
Roger Blumenthal
Edimar A. Bocchi
William E. Boden
Harm Bogaard
Michael Bohm
Roberto Bolli
Marc Bonaca
Raoul Bonan
Sebastien Bonnet
Robert O. Bonow
Munir Boodhwani
Reinier Boon
William B. Borden
Michael Borger
Madeleen Bosma
Zeljko J. Bosnjak
Eduardo Bossone
Kristina L. Bostrom
Rene Botnar
Teodoro Bottiglieri
Rebecca Boxer
Biykem Bozkurt
Johannes Brachmann
Steven M. Bradley
Lisa C. Bratzke
Lynne Braun
Thomas Braun
Eugene Braunwald
Mary Brennan
Mary Brethour
H. Bryan Brewer
Luke P. Brewster
Emmanouil Brilakis
Ralph Brindis
Volker Brinkmann
Meredith Brisco
Michael R. Bristow
Thomas G. Brott
David Brown
Joan Heller Brown
W. Virgil Brown
Michael A. Brownlee
Gerd Brunner
Gil Bub
Chiara BucciarelliDucci
Raffaele Bugiardini
Eileen Bulger
Thomas Bunch
Henning Bundgaard
Allen Burke
Gregory L. Burke
Lora E. Burke
John C. Burnett
Jane C. Burns
Francesco Burzotta
Cheryl Bushnell
Jonathan T. Butcher
Javed Butler
Peter M. Buttrick
Alfred Buxton
Emmanuel S. Buys
Barry J. Byrne
C
Antonio G. Cabrera
Linda Cai
Laura Calabresi
Christopher Caldarone
Colleen Caleshu
Robert M. Califf
Hugh Calkins
Clifton W. Callaway
John Calvert
Duke Cameron
John Camm
Janet Campbell
Lee Ann Campbell
Matthew J. Campen
Umberto Campia
Thomas Cappola
Blase A. Carabello
Shemy Carasso
Teresa Carithers
Lena M.S. Carlsson
S. Thomas Carmichael
Mercedes Carnethon
Melinda J. Carrington
Jo Ann Carson
Ana I. Casanegra
Alberico Catapano
Mark Caulfield
Scott Ceresnak
Marina Cerrone
K. M. John Chan
Mark Y. Chan
Stephen Chan
Vincent Chan
Nisha ChandraStrobos
Ching-pin Chang
Richard Channick
Keith M. Channon
Mark J. Chappell
Mark Chappell
Panithaya
Chareonthaitawee
Seemant Chaturvedi
Edward Chen
Eugene Chen
Jaunian Chen
Jonathan Chen
Ju Chen
Ming Hui Chen
Peng-Sheng Chen
Shih-Ann Chen
Shiyou Chen
Songcang Chen
Yabing Chen
Nipavan
Chiamvimonvat
Alaide Chieffo
William Chilian
Julio Chirinos
W. Randolph
Chitwood
Jaehyung Cho
Byoung Wook Choi
Robin Choudhury
Benjamin Chow
Sheryl L. Chow
Sumita Chowdhury
Catherine Christie
Kabrhel Christopher
Sumeet Chugh
Data
current as of Aug. 20, 2015.
Hyung J. Chun
Mina Chung
Timothy Church
Deborah Chyun
Eugenio Cingolani
Allison Cirino
John M. Clark
John Cleland
James F. Cnota
David Cohen
Mauricio Cohen
William E. Cohn
Lola Coke
Steven D. Colan
Henry M. Colecraft
Helen Colhoun
Sheila Collins
Monica Colvin
Anthony Comerota
Gianluigi Condorelli
Stuart Connolly
Michael S. Conte
Jennifer Lynn Cook
Nancy R. Cook
Daniel H. Cooper
Marco Costa
Maria Rosa Costanzo
John M. Costello
Bernard Cosyns
Thais Coutino
Jessica Coviello
Chad Cowan
Mark A. Creager
Andrew Crean
Maria G. Crespo-Leiro
Alain Cribier
Michael H. Criqui
Rosanne M. Crooke
Bettina F. Cuneo
Anne B. Curtis
Jeptha Curtis
Mary Cushman
William C. Cushman
Christopher Cutler
Donald E. Cutlip
Richard J. Czosek
D
Lisa C. D’Alessandro
Sinan Dagdelen
Ronald L. Dalman
Nicolas Danchin
Stephen Daniels
Alejandro Dapelo Aste
Dawood Darbar
Saumya Das
Patricia Davidson
Leslie L. Davis
Michael E. Davis
Peter Davis
John Day
Sharlene M. Day
Sanjana Dayal
Mark De Caestecker
Sarah De Ferranti
Vinicio De Jesus Perez
Michel de Lorgeril
Frances de Man
Guido de Meyer
Paola De Rango
Menno De Winther
Steven Dean
Arjun Deb
Stephanie Debette
Prakash Deedwania
Emil Degoma
Diego Delgado
Victoria Delgado
Brian Delisle
Paolo Della Bella
Mario Delmar
Donald R. Dengel
Ali Denktas
Cheryl DennisonHimmelfarb
Rahul C. Deo
Genevieve Derumeaux
Matthias Derwall
Akshay Desai
Milind Desai
Sumbul Desai
Jean-Pierre Després
Anita Deswal
Richard Devereux
Cameron Dezfulian
Marcelo Di Carli
Victoria Dickson
Javier Díez
Vasken Dilsizian
Stefanie Dimmeler
Paul DiMusto
Ming Ding
Sanjay Dixit
Ibrahim Domian
J. Kevin Donahue
Erwan Donal
Sharmila Dorbala
Pamela S. Douglas
James Douketis
Michael Dowling
Douglas Drachman
Konstantinos Drosatos
Xiaoping Du
Anne Dubin
Gregory Ducrocq
Jonathan Dukes
Shannon M. Dunlay
Daniel Duprez
Elizabeth Durmowicz
Jason Dyck
Victor J. Dzau
E
Kim A. Eagle
Matthew J. Eagleton
Zubin Eapen
Jo-Ann Eastwood
Ray Ebert
Robert H. Eckel
Thor Edvardsen
Philip Efron
Andrew Einstein
David Eisner
Sanne Eken
Mohammed El Deeb
Gebrine El Khoury
Mikhael F. El-Chami
Patrick T. Ellinor
Perry Elliott
John W. Elrod
Maurice Enriquez
Sarano
Chris Ensor
Slava Epelman
Andrew E. Epstein
Raimund Erbel
David Erlinge
Laura Ernande
Sabine Ernst
Georg Ertl
Mark Eskandari
Murray Esler
Paul Estabrooks
N.A. Mark Estes
Anthony Estrera
Michael Ezekowitz
F
Alik Farber
Peter Faries
Michael E. Farkouh
David P. Faxon
Zahi Fayad
William Fearon
Paul W. Fedak
Francesco Fedele
Vadim Fedorov
Kathleen Fedyszen
Richard Feifer
Ross Feldman
G. Michael Felker
Timothy J. Fendler
Michelle Fennessy
Brian A. Ference
Jane F. Ferguson
Victor A. Ferrari
Gerasimos S.
Filippatos
Michael Fischbein
Anne F. Fish
Glenn Fishman
Robert C. Flaumenhaft
Kirsten Fleischmann
Craig E. Fleishman
Barbara Fletcher
Gerald F. Fletcher
Mark A. Fogel
Alan M. Fogelman
Gregg C. Fonarow
Roger Foo
Randi Foraker
Thomas Force
Paul R. Forfia
Daniel E. Forman
Gary Foster
Keith A. Fox
Gary S. Francis
Gordon Francis
Sheila Francis
Katrien Francois
Nikolaos
Frangogiannis
Sarah Franklin
Stefan Frantz
Julie Freed
Kenneth E. Freedland
Jane E. Freedman
Roy Freeman
Stephen Fremes
Norbert Frey
Mark Friedberg
James Froehlich
Peter C. Frommelt
Toshiro Fujita
Keiichi Fukuda
Shota Fukuda
David R. Fulton
John W. Funder
Karen L. Furie
Valentin Fuster
G
Michael Gaies
Maurizio Galderisi
Nazzareno Galie
Santhi Ganesh
Peter Ganz
Hasan Garan
Madalina Garbi
Jose Garcia
Andrew Gardner
Anna Gawlinski
J William Gaynor
Michael Gaziano
Frederic Geissmann
Caroline A. Genco
Alfred L. George
Richard George
LIor Gepstein
Bernard J. Gersh
Hertzel Gerstein
Robert Gerszten
Tal Geva
Nancy Ghanayem
Joanna Ghobrial
Cecilia M. Giachelli
Jorge F. Giani
Jonathan Gibbins
Gary H. Gibbons
Michael C. Gibbons
Samuel S. Gidding
Therese Giglia
Martine Gilard
Ian Gilchrist
Linda D. Gillam
Thierry C. Gillebert
Thomas Gillette
Dan Gilon
Mark Gladwin
Andrew C. Glatz
Christopher
Glembotski
Michael Glikson
David Glineur
Alan S. Go
Ron Goetzel
David C. Goff
Michael R. Gold
Anne C. Goldberg
Ira J. Goldberg
Lee R. Goldberg
Jeffrey Goldberger
23
Joshua I. Goldhaber
Samuel Z. Goldhaber
Larry B. Goldstein
Michael Gollob
Ramon Gonzalez
Juanatey
Holly C. Gooding
Sarah Goodlin
Philip Gordts
Philip R. Gorelick
Bulent Gorenek
Heather Gornik
Robi Goswami
John S. Gottdiener
K. Lance Gould
Andrew Grace
Kathleen L. Grady
Eric M. Graham
Christopher B.
Granger
Henk Granzier
WIlliam Gray
Barry H. Greenberg
John Greenwood
Igor Gregoric
Hendrik Gremmels
Steven Grinspoon
Leanne Groban
Lars GrosseWortmann
Claudia Grossmann
Jessica Grossmeier
Eberhard Grube
Chad E. Grueter
Christophe Guignabert
Rajiv Gulati
Kristine J. Guleserian
Paul A. Gurbel
Michelle Gurvitz
Tomasz Guzik
Mariann Gyongyosi
H
Richard Ha
Gilbert Habib
Francois Haddad
C. Hadigan
Albert Hagege
Rebecca T. Hahn
Roger Hajjar
Saptarsi Haldar
Jennifer L. Hall
Florencia Halperin
Jonathan L. Halperin
Scott D. Halpern
Naomi Hamburg
Allen Hamdan
John W. Hammon
Göran K. Hansson
Joshua Hare
Robert Harrington
D. Harrison
Ahmed Hasan
Babar Hasan
Gerd Hasenfuss
Paul Hassoun
Stephan Haulon
Edward Havranek
Laura L. Hayman
Mary Fran Hazinski
Jeff S. Healey
David Hehir
Tarek Helmy
Anna Hemnes
Jeroen M. Hendriks
Charles Henrikson
Timothy Henry
Adrian Hernandez
Teri Hernandez
David M. Herrington
Howard C. Herrmann
Richard Heuser
Richard R. Heuser
James Thomas
Heywood
Kathleen Hickey
Robert S. Higgins
Charles Hill
Joseph A. Hill
Gerhard Hindricks
Rabea Hinkel
Loren F. Hiratzka
Alan T. Hirsch
Jennifer C. Hirsch
Marie-France Hivert
Carolyn Ho
Vincent B. Ho
Judith Hochman
Udo Hoffmann
Ulrich Hofmann
Brian D. Hoit
David Holmes
Geu-Ru Hong
Ting-Ting Hong
Michael Hope
Lisa Hornberger
Jay Horton
Steven R. Houser
Virginia J. Howard
Tzung K. Hsiai
Patrick C.H. Hsieh
Daphne T. Hsu
Priscilla Hsue
Dayi Hu
Erich Huang
Kurt Huber
Christopher
Hugo-Hamman
Scientific Sessions’ faculty — experts in various aspects of cardiovascular health and science —
will share their experiences and expertise. Come and hear what they have to say.
24
Marc Humbert
Scott L. Hummel
Yong Huo
Karen Huss
Elaine Hylek
I
Gianluca Iacobellis
John Ikonomidis
Frank F. Ing
Thomas Inge
Jodie Ingles
Ignacio Inglessis
Silvio Inzucchi
Matthew Ito
Joachim Ix
J
Alice K. Jacobs
Jeffrey Jacobs
Jill Jacobs
Marshall L. Jacobs
Terry A. Jacobson
Iris Jaffe
Farouc Jaffer
Mukesh Jain
Jose Jalife
Cindy James
Stefan K. James
Karin A. JandeleitDahm
Ewa A. Jankowska
Jan Janousek
James Januzzi
Christine Jellis
Kathy Jenkins
Catriona S. Jennings
Mark Jeong
Michael
Jerosch-Herold
Mariell Jessup
Wendy Jessup
Zhang Jian
LI Jianping
Zheng Gen Jin
Hani Jneid
Hanjoong Jo
Roby Joehanes
Anitha John
Heather Johnson
Jason Johnson
Maryl Johnson
Rachel Johnson
Peter Jones
Steven R. Jones
Steven P. Jones
Susan Joseph
Karen E. Joynt
Daniel Judge
Markus Juonala
K
Stefan Kaab
Annemarie Kaan
Ashish Kabra
Susan Kahn
Ajay K. Kakkar
Kamyar KalantarZadeh
Jonathan Kaltman
Timothy Kamp
Peter M. Kang
Joshua Kanter
David P. Kao
Samir Kapadia
Navin Kapur
Saibal Kar
Keyvan KarimiGalougahi
Juan C. Kaski
Robert Kass
John J. Kastelein
Sekar Kathiresan
Peter Katzmarzyk
John Kaufman
Rae-Ellen Kavey
Clifford J. Kavinsky
Dhruv S. Kazi
Aaron S. Kelly
Daniel P. Kelly
Walter Kernan
Kiarri Kershaw
Bryan Kestenbaum
Christopher Kevil
Paul Khairy
Faisal Khan
Amit Khera
Eugene G. Kholmovski
Alok Khorana
Bob Kiaii
Gregory Kicska
Michael Kiernan
Ahmet Kilic
Kee Sik Kim
Soo Hyun Kim
Carey D. Kimmelstiel
TEST YOUR
CARDIAC
SKILLS
SIMULATION ZONE
IN
THE
BODY INTERACT
The virtual patient in this
innovative, life-like cloud platform
comes with dynamic monitoring,
dialoguing, test orders, scans,
drugs, intervention options and
performance debriefing. Medical
case scenarios presented on the immersive 3D touchscreen are
problem-based in areas such as stroke, atrial fibrillation and heart failure.
MECHANICAL CIRCULATORY SUPPORT
This hands-on opportunity allows you to model critical scenarios and
observe hemodynamic consequences. A total artificial heart mock
circulatory loop paired with axial and centrifugal continuous flow
devices will test scenarios such as inadequate preload/afterload
conditions, right heart failure and device obstruction.
Visit the Simulation Zone in booth 101 during scheduled sessions or drop by
at your convenience to experience the devices on your own. The schedule of
sessions will be available for viewing in the Mobile Meeting Guide App (available for
download in mid-October) and in the Final Program available on-site.
George King
Bronwyn Anne
Kingwell
Scott Kinlay
Raj Kishore
Eddy Kizana
Jesper Kjaergaard
Allan Klein
Dawn Kleindorfer
Monica E. Kleinman
Jeffrey Kline
N. Jennifer Klinedinst
Paul Knaapen
Joshua Knowles
Walter Koch
Robb D. Kociol
Wolfgang Koenig
Kwang Koh
Lisa Kohr
Michel Komajda
Issei Komuro
Marvin Konstam
Maria Kontaridis
Michael C. Kontos
Anatol Kontush
Jelena Kornej
Mikhail Kosiborod
Andrew Krahn
Christopher M. Kramer
Litsa Kranias
William Kraus
Catherine Krawczeski
Thomas Krieg
Penny Kris-Etherton
Karl-Heinz Kuck
Bernhard Kuhn
Alexander Kulik
Hemant Kulkarni
Raman Krishna Kumar
Uday Kumar
Sawan Kumar Jha
Sonia Kunstmann
Bonnie Ky
L
Mark La Meir
Ronald V. Lacro
Neal Lakdawala
Carolyn S. Lam
Pier Lambiase
Rachel J. Lampert
Patrizio Lancellotti
Michael Landzberg
John Lane
Irene M. Lang
26
Jason Lang
Emmanuel Lansac
Michael Lauer
Carl Lavie
Nathan Lawson
Jennifer Lawton
Pietro Enea Lazzerini
Anson Lee
Christopher S. Lee
Dongwon Lee
Jason Lee
Maarten J. Leening
Barbara Leeper
Nicholas Leeper
David J. Lefer
Leslie Leinwand
Jonathon Leipsic
Lawrence Leiter
Martin Leon
Jonathan Leor
Annarosa Leri
Glenn N. Levine
Robert A. Levine
Emily B. Levitan
Daniel Levy
Jerrold H. Levy
Jack C. Lewin
Gregory Lewis
Lisa Lewis
Tene Lewis
Jin Li
Ren-Ke Li
Renhao Li
Mingyu Liang
Ronglih Liao
Peter Libby
Alice H. Lichtenstein
Joao Lima
Joy Lincoln
JoAnn Lindenfeld
Arne Lindgren
Merry Lindsey
Charlotte Ling
Mark Link
Gregory Lip
Steven E. Lipshultz
Kasia J. Lipska
M. Teresa T. Lira
Harold Litt
Stephen Little
Sheldon Litwin
Sarah Livesay
Donald M. LloydJones
Barry London
Gary Lopaschuk
Francisco LopezJimenez
Jose Luis LopezSendon
Joseph Loscalzo
Steven Lubitz
Thomas F. Lüscher
James M. Luther
M
Daqing Ma
Calum A. MacRae
Michael Madani
Thomas Maddox
Meenakshi Madhur
Ahmed Magdy
Elizabeth Magnuson
Felix Mahfoud
Ehtisham Mahmud
Lynn Mahony
Marjorie S. Maillet
Francesco Maisano
Mark W. Majesky
Maulik Majmudar
Ziad Mallat
Simon Maltais
Alice Maltret
Rekha Mankad
Sunil V. Mankad
Douglas L. Mann
Warren Manning
Ganesh Manoharan
JoAnn E. Manson
Eduardo Marban
Francis Marchlinski
James Marcin
Gregory M. Marcus
Ariane Marelli
Kenneth Margulies
Daniel B. Mark
Michael Markl
Bradley Maron
James F. Martin
Kathleen A. Martin
Alejandro Martinez
Tami Martino
Tom Marwick
Justin C. Mason
Frederick A. Masoudi
Verghese Mathew
Scot Matkovich
Dan Matlock
Hiromi Matsubara
Chisa Matsumoto
David L. Mattson
Nicola Maurea
Mathew Maurer
Laura Mauri
Kreton Mavromatis
Manuel Mayr
Janine M. Mazabob
Mervyn Maze
Mjaye L. Mazwi
Pamela J. McCabe
Patrick M. McCarthy
Kathleen McCauley
Michael V. McConnell
Brian McCrindle
Peter A. McCullough
Mary McDermott
Alicia A. McDonough
Tom McElderry
Carmel McEniery
Anthony W. McGuire
Colleen K. McIlvennan
Timothy A. McKinsey
Vallerie V. McLaughlin
Julie R. McMullen
John McMurray
Elizabeth McNally
Robert L. McNamara
Jessica L. Mega
Mandeep R. Mehra
Roxana Mehran
Puja K. Mehta
James B. Meigs
Liu Meilin
Jolyane Meloche
Matthew Menard
Venugopal Menon
George Mensah
Laura Mercer Rosa
Raina Merchant
Luc Mertens
Thierry Mesana
Markus Meyer
Deborah Meyers
Joseph Miano
Evangelos D.
Michelakis
Hector Michelena
Lisa Mielniczuk
Jennifer H. Mieres
Ricardo Migliore
Anastasia S.
Mihailidou
David J. Milan
Carmelo Milano
Dianna Milewicz
Federico Milla
John Miller
Leslie W. Miller
Luann Minich
Margo Minissian
Gary S. Mintz
Mahek Mirza
Paras Kumar Mishra
Seema Mital
Yoshihide Mitani
William E. Mitch
Gary Mitchell
DImitrios Mitsouras
Christina Y. Miyake
Sara Mobasseri
Peter J. Mohler
Carlos A. Molina
Jeffery D. Molkentin
Paul Monagle
David Montani
Jean Moody-Williams
Philip Moons
Shirley M. Moore
Samia Mora
Victor Morell
Carlos A. Morillo
Nicholas Morrell
Shaine Morris
Debra K. Moser
Ivan Moskowitz
Javid Moslehi
Richard Moss
Patrick Most
Mahasin Mujahid
Elizabeth Murphy
Michael Murphy
Jenna M. Murray
Niren Murthy
Vemuri S. Murthy
Venkatesh L. Murthy
Kiran Musunuru
Jonathon Myers
N
Gerald Naccarelli
Sathyamangla V. Naga
Prasad
Eike Nagel
Sherif Nagueh
Matthias Nahrendorf
Atsushi Nakano
Satoshi Nakatani
Vijay Nambi
Navin C. Nanda
Nawazish Naqvi
Sanjiv Narayan
Jagat Narula
Andrea Natale
Meena Nathan
Stanley Nattel
Saman Nazarian
Sean-Xavier Neath
Mona Nemer
Petr Neuzil
Jane W. Newburger
L. Kristin Newby
Kim Newlin
Christopher
Newton-Cheh
Tien Ng
Elsie Nguyen
Graham Nichol
Mark Nicolls
Jo Ann Nieves
Petros
Nihoyannopoulos
Ravi Nistala
Thilo Noack
Jerzy Roch Nofer
Raul G. Nogueira
Anju Nohria
Borge Nordestgaard
Samar Noureddine
O
Christopher J.
O’Donnell
Patrick T. O’Gara
Christopher O‘Connor
Anush Oganesian
Takeshi Ogo
Young S. Oh
Vahagn Ohanyan
Jeffrey W. Olin
Guillermo Oliver
Iacopo Olivotto
Brian Olshansky
Eric N. Olson
Anders G. Olsson
Suzanne Oparil
Ali Oto
Oztekin Oto
Kinya Otsu
Catherine M. Otto
Jingsong Ou
Bruce Ovbiagele
Neville Owen
Anjali Tiku Owens
Christopher D. Owens
P
Douglas L. Packer
Milton Packer
Francis D. Pagani
Patrick J. Pagano
Richard Page
Robert L. Page
Stephen Page
Elfriede Pahl
Igor F. Palacios
Latha Palaniappan
Miguel Pampaloni
Reena L. Pande
Peter S. Pang
David Paniagua
Bishnu Panigrahi
Angelo A. D. Paola
Anand Parekh
Nisha Parikh
Seong-Mi Park
Seung Woo Park
Sara Pasquali
Robert H. Pass
Mitesh Patel
J. Herbert Patterson
Kristen Patton
Nina Paynter
William F. Peacock
Thomas A. Pearson
Carlos Pedra
Patricia A. Pellikka
Michael Pencina
Daniel Penny
Carl J. Pepine
Naveen Pereira
Néstor G. Pérez
Emerson C. Perin
Frederic Perros
Karlheinz Peter
Nicholas Peters
Eric D. Peterson
Randall Peterson
Anna S. Petronio
Gosta B. Pettersson
Michael Petty
Duc Thinh Pham
Melanie Philipp
Mariann Piano
Gregory Piazza
Philippe Pibarot
Michael H. Picard
Jonathan Piccini
Luc Pierard
Anna Pilbrow
Ileana L. Pina
Peipei Ping
Duane Pinto
Fausto Pinto
Bertram Pitt
Geoffrey S. Pitt
Kian-Keong Poh
Paul Poirier
Venkateshwar Polsani
Piotr Ponikowski
Zoran Popovic
Athena Poppas
Wendy Post
Janet Powell
Tiffany M. Powell-Wiley
Bunny J. Pozehl
Sumanth Prabhu
Aruna Pradhan
Siddharth Prakash
Abhiram Prasad
Randy Prather
Charlotte A. Pratt
Bernard Prendergast
Richard Price
Juan Carlos Prieto
Silvia G. Priori
Vincent Probst
Steve Provencher
Janet Prvu Bettger
Bruce Psaty
William Pu
Yuh Fen Pung
Kuberan Pushparajah
John Puskas
Houry Puzantian
Q
Zhen Qian
Candida C. Quarta
Arshed A. Quyyumi
R
Marlene Rabinovitch
Daniel J. Rader
Wolfgang A.K. Radtke
Gilbert Raff
Mohammed Yusoff
Rahal
Vivek Rajagopal
Sanjay Rajagopalan
Basel Ramlawi
Janani Rangaswami
Gadiparthi Rao
Sunil V. Rao
More than 1,500 faculty will present during Scientific Sessions 2015.
Antonio Rapacciuolo
Ravi Rasalingam
Helge H. Rasmussen
Anis Rassi
Suman Rathbun
Vinod Ravi
Patricia Reant
Michael J. Reardon
Rita Redberg
Gautham P. Reddy
Vivek Reddy
Nancy Redeker
Margaret M. Redfield
Andrew Redington
Judith Regensteiner
Vera Regitz Zagrosek
Muredach P. Reilly
Benjamin Reinking
Jared P. Reis
Carol Remme
Kathryn M. Rexrode
Harmony R. Reynolds
Matthew Reynolds
Henrique B. Ribeiro
Michael W. Rich
Paul M. Ridker
Barbara Riegel
Niels Riksen
Sarah Rinehart
Clint Robbins
Jeffrey Robbins
Susan Roberts
Jennifer G. Robinson
Petra Rocic
Howard Rockman
Stanley Rockson
Dan Roden
Jo Ellen Rodgers
Carlos J. Rodriguez
Veronique L. Roger
Anand Rohatgi
Alvaro Rojas-Pena
Mary J. Roman
Jonathan Rome
Matthew Rondina
Emilio Ros
Jonathan Rosand
Raphael Rosenhek
Stefan Rosenkranz
David Rosenthal
Heather Ross
Robert Ross
Greg Roth
Beverly A. Rothermel
Gary S. Roubin
Faye Routledge
R. Daniel Rudic
Marc Ruel
Zaverio Ruggeri
Marta Ruiz-Ortega
Paolo Rusconi
Mark W. Russell
John Ryan
Frank J. Rybicki
Jack Rychik
Kerry-Anne Rye
S
Marc Sabatine
Craig Sable
Ritu Sachdeva
Frank Sacks
Sakthivel Sadayappan
Junichi Sadoshima
Susmita Sahoo
Yoshikatsu Saiki
Hajime Sakuma
Sameh Salama
Susan Saleeb
Anne Sales
Nilesh Samani
Alejandra San Martin
Eduardo Sanchez
Pedro Sanchez
Prashanthan Sanders
Darshak Sanghavi
Monika Sanghavi
Raul Santos
Carlos G. SantosGallego
Mark Sarnak
Jonathan Satin
Toru Satoh
Naveed Sattar
Jeff Saucerman
William Henry Sauer
Jacqueline Saw
Douglas Sawyer
Michael Sayre
Mauricio Scanavacca
Philip Schauer
Melvin M. Scheinman
Ralph Schermuly
Marielle ScherrerCrosbie
Mark A. Scheurer
David Schidlow
Ernesto Schiffrin
Ann Marie Schmidt
Boris Schmidt
Michael Schneider
Jeanette
Schulz-Menger
P. Christian Schulze
Andrew Schwartz
Peter Schwartz
Steven Schwartz
Benjamin Scirica
Jane D. Scott
Christine Seidman
Alexander Seifalian
Christian Seiler
Frank Sellke
Marc Semigran
Christopher Semsarian
Sue Sendelbach
Yoshihiro Seo
Patrick W. Serruys
Rose B. Shaffer
Dipan J. Shah
Maully Shah
Mitesh Shah
Sanjiv Shah
Svati H. Shah
Tina Shah
Catherine Shanahan
Oz Shapira
Sanjay Sharma
Leslee Shaw
Robin Mark Shaw
Christina M. Shay
Soren P. Sheikh
27
Lara Shekerdemian
Win Kuang K. Shen
Matthew W. Sherwood
Chi Young Shim
Hiroaki Shimokawa
Andrew Y. Shin
Mehdi Shishehbor
Kalyanam Shivkumar
Ralph Shohet
Rosa Sicari
Horst Sievert
Jennifer Avari Silva
Candice Silversides
Craig Simmons
Kit N. Simpson
Daniel Singer
Pranava Sinha
Karin Sipido
Hamayak Sisakyan
Olivier Sitbon
Steven Small
Nicholas Smedira
Jonathan D. Smith
Peter Smith
Sidney C. Smith
Steven Smith
Kim Smolderen
Harold Snieder
Piotr Sobieszczyk
John Solaro
Scott D. Solomon
Prem Soman
Virend K. Somers
lars Sondergaard
Erica Sood
John Spertus
Thomas L. Spray
Bonnie Spring
Christopher Spurney
Deepak Srivastava
Sanjay Srivastava
Marie-Pierre St-Onge
Julie St-Pierre
Randall Starling
Sandy Staveski
Charles
Steenbergen Jr.
Philippe Gabriel Steg
Michael Steigner
Paul Stein
Benjamin A. Steinberg
Julia Steinberger
Steven Steinhubl
Elaine E. Steinke
Kurt R. Stenmark
Elizabeth Stephenson
David Stepp
28
Lynne Warner
Stevenson
William G. Stevenson
Duncan J. Stewart
Garrick Stewart
Arthur Stillman
Nathan Stitziel
Neil J. Stone
Karen Stout
Sharon Straus
Mary Straw
Erik Stroes
Anna Strömberg
Wilber Su
Anne E. Sumner
Zhongjie Sun
Kjetil Sunde
Mark A. Sussman
Robert Sutton
Erik Suuronen
Karl Swedberg
Nancy Sweitzer
Keith Swetz
Filip K. Swirski
David M. Systrom
T
Tamas Szili-Torok
Ira Tabas
Sarah Tabbutt
Heinrich Taegtmeyer
Kei Takahashi
Masafumi Takahashi
Masaaki Takeuchi
Alan R. Tall
Jacqueline TamisHolland
Ru San Tan
Hidekazu Tanaka
Wilson Tang
Victor F. Tapson
Jil C. Tardiff
Herman A. Taylor
W. Robert Taylor
Ruth Taylor-Piliae
Patrick J. Tchou
John R. Teerlink
Martin Teraa
Cesare Terracciano
Paul Terry
Jeffrey Testani
Jeff Teuteberg
Paaladinesh
Thavendiranathan
Thenappan
Thenappan
Judith Therrien
Ravi Thiagarajan
Dierk Thomas
Gregory Thomas
Randal Thomas
Sara Thorne
Vinod H. Thourani
Thomas Thum
Kristian Thygesen
Rong Tian
Jens M. Titze
Stefano Toldo
Eser Tolunay
Gordon F. Tomaselli
Bonnie Tong
Rhian Touyz
Jeffrey A. Towbin
Dwight A. Towler
Raymond Townsend
Mark I. Travin
Diane Treat-Jacobson
Jennifer Tremmel
Jennifer Trilk
Le Trinh
Emily J. Tsai
Connie Tsao
Omaç Tufekcioglu
Mintu Turakhia
James R. Turk
Sony Tuteja-Stevens
James S. Tweddell
Marysia Tweet
Anne Tybjaerg-Hansen
U
James Udelson
Elaine Urbina
Masuko Ushio-Fukai
V
Miguel Valderrabano
Anne Marie Valente
Glen S. Van Arsdell
Jop H. van Berlo
Frans Van de Werf
Pim Van Der Harst
Peter Van Der Meer
Jolanda Van Der
Velden
Jennifer Van Eyk
Isabelle C. Van Gelder
Linda Van Horn
Eva van Rooij
Toon van Veen
David R. Van Wagoner
Mani A. Vannan
Orly Vardeny
Stephanie Vaughn
Ashley Vavra
Rajesh Vedanthan
Hugo Moreno
Velazquez
Ercole Vellone
Luigi Venetucci
Lakshmi
Venkitachalam
Hector O. Ventura
Arie Verkerk
Atul Verma
Subodh Verma
Hillary J. Vernon
Kasey C. Vickers
Ronald Victor
Mladen Vidovich
Julie Vincent
Salim S. Virani
Pierre Voisine
Thomas M. Vondriska
Marc Vos
Pascal Vranckx
W
Reza Wakili
Ron Waksman
David Wald
Jennifer Walker
Michelle Wallace
Lars Wallentin
Edward Walsh
Kenneth Walsh
Dirk Walter
Da-Zhi Wang
Hong Wang
Paul J. Wang
Thomas Wang
Tracy Wang
Xuejun Wang
Yibin Wang
Steven Warach
Stephanie Ware
Jason H. Wasfy
Nozomi Watanabe
Hugh C. Watkins
Karol E. Watson
Connie Weaver
Christian Weber
Gregory Webster
Xander Wehrens
Guy Weigold
William Weintraub
Richard Weisel
Jeffrey Weitz
Hein Wellens
Cheryl Wellington
Robert C. Welsh
Nanette Wenger
Gil Wernovsky
Jennifer Wessel
Paul K. Whelton
Nathan J. White
John Whitlock
Debra Wiegand
Anthony Wierzbicki
Anthony S. Wierzbicki
Georg Wieselthaler
David J. Wilber
Joellen Wilbur
Christopher S. Wilcox
Peter Willeit
David O. Williams
Gordon Williams
Kim A. Williams
Mathew R. Williams
Monte Willis
Melissa Wilson
Peter Wilson
Joseph Witztum
Myles Wolf
Jessica G. Woo
Joseph Woo
David A. Wood
David Wood
Kathryn Wood
Pamela Woodard
Bradford B. Worrall
Clinton B. Wright
Jackson T. Wright
Janet S. Wright
R. Scott Wright
Connie Wu
Joseph C. Wu
Mei-Hwan Wu
Sean Wu
X
Chen Xiaoyuan
Qingbo Xu
Y
Jay Yadav
Steven J. Yakubov
Clyde W. Yancy
Phillip C. Yang
Xiao-Feng Yang
Demetris Yannopoulos
Zemin Yao
Bernice Yates
Dileep R. Yavagal
Yerem Yeghiazarians
Edward Yeh
Robert Yeh
Liya Yin
Gerald Yonga
Shi-Joon Yoo
Michael Yost
Deborah R. Young
Martin E. Young
Cheuk-Man Yu
Paul B. Yu
Salim Yusuf
Katherine E. Yutzey
Z
Justin P. Zachariah
Evan Zahn
Osama O. Zaidat
Alexander Zambon
Jose Luis Zamorano
Steven Zangwill
Faiez Zannad
David C. Zawieja
Andreas Zeiher
Mary Zellinger
Parounak A. Zelveian
Julie J. Zerwic
Uwe Zeymer
Jianyi Zhang
Dong Zhao
Li-Ru Zhao
Xiao Zhou
Cheng Zhu
Khaled Ziada
Michael R. Zile
Peter Zimetbaum
William Zoghbi
Ming Zou
Coert Zuurbier
AMP UP
your Scientific Sessions experience
More can’t-miss opportunities
• EP Central
• HealthTech Competition
• Simulation Zone
• Meet the Trialist
• Complimentary coffee breaks
• Free lunch in Product Theaters
• AHA HeartQuarters
• Engage with more than
200 exhibitors
• Hands-on CPR training
• AHA Bistro
• FREE professional photos taken
• Complimentary Wi-Fi lounge
and charging stations
SCIENCE & TECHNOLOGY HALL HOURS | Nov. 8: 11 a.m. – 4 p.m. | Nov. 9: 10 a.m. – 4 p.m. | Nov. 10: 10 a.m. – 2:30 p.m.
SCIENCE & TECHNOLOGY HALL/UNOFFICIAL SATELLITE EVENTS
TECHNOLOGY
VISIT THESE 2015 EXHIBITORS
A–C
A Fashion Hayvin, Inc.
Accusplit Make a Difference Programs,
Actelion Pharmaceuticals US Inc
ADInstruments, Inc
Advanced Cooling Therapy, Inc.
Advocate Children’s Hospital
AHA Hands-Only CPR Training
AHA HeartQuarters
AliveCor, Inc.
AltaThera Pharmaceuticals
Amarin Pharma plc
Ambry Genetics
American Board of Clinical Lipidology
American College of Cardiology
Amgen
Arbor Pharmaceuticals
Arrhythmia Alliance
AstraZeneca Pharmaceuticals
AtCor Medical Inc.
Banyan
Bayer Healthcare
Blueprint Genetics
BMS/Pfizer
Boehringer Ingelheim Pharma, Inc.
Cardiology Today and Healio.com By Slack Inc.
CellAegis Devices Inc.
Channing Bete Co.
Children’s Medical Center of Dallas
30
China Heart Federation (CHF)
ContextMedia Health
Coravin
Cyfuse Biomedical KK
Cytokinetics
D–F
Daiichi Sankyo, Inc.
Dassault Systèmes SIMULIA
DMT-USA, Inc.
Duke Clinical Research Institute
Edwards Lifesciences
Egg Nutrition Center
Eko Devices
Elsevier
Emerging Science & Technologies
emka Technologies Inc.
Fukuda Denshi
G–I
Genzyme a Sanofi Company
Gilead Sciences, Inc.
Hawaiian Moon
HeartSine Technologies
HeartWare
Hitachi Aloka Medical
Hugo Sachs Elektronik/Harvard Apparatus
Ideal Protien of America, Inc.
IEM
Infinite Therapeutics
Intermountain Heart Institute
Inventive Medical Ltd (Heart Works)
InvivoSciences Inc.
IonOptix
Itamar Medical
J–L
The JAMA Network
Janssen Pharmaceuticals, Inc.
The Japanese Circulation Society
John Welsh Cardiovascular Diagnostic Lab
The Joint Commission
Karger Publishers
Laerdal Medical
M–O
Mayo Clinic
Mayo Clinic Cardiovascular Self-Study Tutorials
Med Learning Group
Medicure
Medley Farmaceutica
Medtronic
Merck
Millar, Inc.
MNG Laboratories
Mortara Instrument, Inc.
Multi Channel Systems
National Death Index
National Kidney Foundation
National Lipid Association
NEJM Group
Nihon Kohden America
NorthEast Monitoring, Inc.
Northwestern Medicine
Novartis Pharmaceuticals Corp.
Oxford University Press
P–S
Panasonic Healthcare Corp.
Panasonic Wellness
Perosphere Inc.
Pfizer Inc.
Physio-Control
Pikeville Medical Center, Inc.
Portola Pharmaceuticals, Inc.
Pozen
Preventive Cardiovascular Nurses Assn. PCNA
PromoCell GmbH
QGenda, Inc.
Relypsa Inc.
Sanofi
Sanofi / Regeneron
Scarf King
Seahorse Bioscience
Sony Biotechnology
Stocosil
Stryker
EXHIBITOR HIGHLIGHTS
Thank you to the following exhibitors that
have supported the Scientific Sessions
Conference Preview.
T–Z
Taylor and Francis
theheart.org/Medscape Cardiology
Thoratec Corp.
TIMI Study Group
TSE Systems, Inc.
UF Health Shands Hospital
UltraScope
VisualSonics
W.A. Baum Co., Inc.
Wake Forest Innovations
Wiley
Wolters Kluwer
WorldPoint
ZOLL Medical Corp.
ZS Pharma
The Science & Technology Hall will be open from 11 a.m. to 4 p.m., Sunday, Nov. 8; 10 a.m. to
4 p.m., Monday, Nov. 9; and 10 a.m. to 2:30 p.m., Tuesday, Nov. 10.
31
CARDIOVASCULAR
EXPERT THEATERS
DATE/TIME
S
pend your lunch time at the Cardiovascular Expert Theaters, located in the
Science & Technology Hall. Sessions given by industry supporters will
introduce you to the latest cardiovascular products on the market. Complimentary
lunch provided.
BOOTH
SUPPORTER
11:15 a.m.-Noon
Booth 1601
Amgen
11:15 a.m.-Noon
Booth 163
Amarin Pharma
11:15 a.m.-Noon
Booth 1559
Sanofi-Regeneron
12:30–1:15 p.m.
Booth 1601
Janssen Pharmaceuticals, Inc.
12:30–1:15 p.m.
Booth 163
Pfizer
12:30–1:15 p.m.
Booth 1559
Amgen
Noon-12:45 p.m.
Booth 1601
Sanofi-Regeneron
Noon-12:45 p.m.
Booth 163
Merck
Noon-12:45 p.m.
Booth 1559
Amgen
1:15-2 p.m.
Booth 1601
Boehringer Ingelheim Pharmaceuticals, Inc. and Medtronic
1:15-2 p.m.
Booth 163
Amgen
1:15-2 p.m.
Booth 1559
Novartis Pharmaceuticals Corporation
Noon-12:45 p.m.
Booth 1601
Amgen
Noon-12:45 p.m.
Booth 163
Boehringer Ingelheim Pharmaceuticals, Inc.
Noon-12:45 p.m.
Booth 1559
1:15-2 p.m.
Booth 1601
1:15-2 p.m.
Booth 163
Relypsa, Inc.
1:15-2 p.m.
Booth 1559
AstraZeneca
SUNDAY, NOV. 8
MONDAY, NOV. 9
TUESDAY, NOV. 10
Two sets of Cardiovascular Expert Theaters will be offered each day on Sunday, Nov. 8; Monday, Nov. 9 and Tuesday, Nov. 10.
32
Grow Your
Professional Network
at Scientific Sessions 2015
You may be early in your career, a seasoned physician or a researcher.
No matter the career or specialty, the connections you make during
Sessions will extend your knowledge and help you enhance your
professional mission and ultimately patient outcomes.
Find the right networking environment for you:
• Meet the Trialists: Connect with the researchers involved in
some of the biggest trials of 2015.
• EP Central: A new place for electrophysiologists and others interested
in EP to exchange information and relax.
• Early Career: Gather career-building resources and engage with senior
investigators in a full day of sessions, networking events and a lounge.
• Science & Technology Hall: Visit with 200+ exhibiting companies
showcasing the latest cardiovascular technology and resources.
• Poster Hall: Have one-on-one conversations with poster presenters
and top researchers.
• Members-Only Activities: Enjoy AHA Scientific Council meetings,
committee meetings, council dinners, luncheons, lounges and more!
• Science Subcommittee Collaboration Station: Learn how you can
be a part of the 35 essential AHA Science Subcommittees.
scientificsessions.org
#AHA15
Photos ©2014 AHA/Todd Buchanan
Join the industry’s global elite and register today
for a chance to grow your professional connections.
LEARNING
MONDAY, NOV. 9
EVENING
Secondary Prevention of Atherothrombotic
Events: Current Insights on Advancing Science
Provided by Vindico Medical Education
Supported by Merck & Co.
UNOFFICIAL SATELLITE EVENTS
Registration link: www.vindicocme.com/110815
SATURDAY, NOV. 7
SUNDAY, NOV. 8
Sponsored by Voxmedia
AFTERNOON
EVENING
Registration link: www.symposiareg.com/21513
Acute Coronary Syndrome in Younger Women:
Unique Risks, Etiologies, Treatments and
Opportunities
Cardio-Oncology — A New Era,
An Evolving Discipline
TUESDAY, NOV. 10
An Expert Forum: Hot Topics in Stable Ischemic
Heart Disease Management
Supported by Gilead Sciences Medical Affairs
Sponsored and supported by the Mayo Clinic
MORNING
Sponsored and supported by the Mayo Clinic
Optimizing LDL Targeted Cardiovascular
Risk Reduction
EVENING
Sponsored by the University of Massachusetts
Management of Hypertrophic Cardiomyopathy
for the Clinical Cardiologist
Supported by Sanofi and Regeneron
Sponsored by Washington University School
Registration link: www.reg-LDL.com
Medical School
Pharmaceuticals
of Medicine Continuing Medical Education
AF Spotlight: Using NOACs Safely
Supported by Washington University and
Barnes-Jewish Heart & Vascular Center
Sponsored by the Postgraduate Institute for
Registration link: BarnesJewish.org/orlando2015
Medicine and Medtelligence
A 3-D View Statin Therapy — Only Part of
a Comprehensive Approach to Dyslipidemia
Management
Sponsored by Med Learning Group
Supported by an educational grant from Eli Lilly
Challenges in Cholesterol Management What Your Patients Might Not Be Telling You:
A Town Hall Symposium
Sponsored by Global Academy for Medical
Supported by Boehringer Ingelheim
Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.
Education
Supported by Pfizer
Registration link: events.medtelligence.net/ha2015.
html
Industry supported symposia
34
University non-profit symposia
EXPECT
BIG Science
BIG Clinical Content
BIG Technology
BIG Networking
See why Scientific Sessions is the
global conference of choice for
cardiovascular professionals.
THINGS
23
17,000
RESEARCHERS • CLINICIANS • NURSES
+1.5 million
a Global
Perspective
FROM
SPECIAL & NAMED
lectures
countries
45% international
55% domestic
who attends:
EMTs • Technicians • Pharma • Students • Early Career
the
BEST
science
+
5,000
presentations
INCLUDING
1,500 FACULTY
INVITED
4,000 ABSTRACTS
LATEST-BREAKING Clinical Trials
ARRHYTHMIA
RESEARCH SUMMIT
Cardiovascular Nursing
Clinical Symposium
ReSS
are now part of
SCIENTIFIC
SESSIONS
30
programming
tracks
INCLUDES 3 NEW
TRACKS:
CARDIOVASCULAR
PROFESSIONALS
virtual attendees
200+ exhibitors
technology + resources
Hands-on
activities
in new
SIMULATION
ZONE
Become a
PROFESSIONAL
MEMBER
and save up to
Clinical Trialists
Health Tech
on registration
Workplace Health
Register by September 9 to take advantage
of early registration and book housing.
Exhibits: November 8–10 | Sessions: November 7–11
$400
CONTINUING
EDUCATION
credits available
LEARN MORE
scientificsessions.org/registrationandhousing
DISCOVER ORLANDO
FUN IN ORLANDO
TAKE OFF
As one of the most popular destination
cities in the world, Orlando is
accustomed to handling a crowd — the
city saw more than 62 million visitors
last year alone. Orlando International
Airport is only a 25-minute drive from
the Orange County Convention Center
and offers thousands of non-stop
flights. You should book your flight early
for the best times and fares.
• AHA Travel Service: 800-999-9717,
Monday-Friday, 8 a.m.-6 p.m. CST
• American Airlines: 800-221-2255
• Your own travel agent
36
Visit Orlando
W
hen it comes to destination
cities, Orlando, Florida,
ranks among the biggest.
Home to more than a dozen
theme parks, the magic of the
city doesn’t end there. More than 100 other
attractions help secure Orlando’s spot on nearly
every vacation Top 10 list, as well as validate
its distinction as the most visited destination
in the country. Once the meeting is adjourned,
world superb restaurants, championship golf
courses, world-class spas, captivating museum
exhibitions and more than 1,200 retail shops
await you. Whether you’re looking for a quick
getaway after meetings or an all-day excursion
for your accompanying family or friends,
Orlando offers something for every schedule
and interest. Swim with dolphins, play 18 holes
on a world-class golf course, dine in some of
the most inspired restaurants in the world or,
yes, conquer the roller coasters. Orlando has the
perfect adventure for you. Screamin’ Gator Zip Line at Gatorland
BLUE MAN GROUP AT
UNIVERSAL ORLANDO
bluemanorlando.com
This world-renowned show is a curiously
captivating mash-up of totally unique live
music, unexpected humor and lots of paint.
The group’s inventive comedy and audience
interaction with multimedia theatrics combine
to create a blissful party atmosphere.
CAPONE’S DINNER & SHOW
alcapones.com
Become a member of a Chicago crime
family. At this “family gathering,” you’ll be
informed by Al Capone himself about a “rat”
in the organization and asked to help “take
care of it.” The entire staff and audience
participate in the fun, which includes an allyou-can-eat dinner buffet.
CLEARWATER MARINE AQUARIUM
seewinter.com
The world’s best-known marine life rescue
center is home to Winter, the world’s most
famous dolphin and star of the major motion
picture Dolphin Tale. You’ll also see Atlantic
bottlenose dolphins, sea turtles, river otters,
sting rays and sharks at the aquarium. It’s
worth the trip.
KISSIMMEE SWAMP TOURS
kissimmeeswamptours.com
Explore 35,000 acres of untouched wild
beauty; no development, no houses. This
DISCOVER ORLANDO
guided airboat tour will take you through
pristine swamps and marshes in the Orlando
and Kissimmee area to see the “old Florida.”
ripleys.com/orlando
An unbelievable variety of artifacts and
displays in 16 unique galleries that pay
tribute to the odd and the strange, inspired
by Robert Ripley himself. Marvel at the
collection of weird and unusual relics during
this self-guided, self-paced tour. The unusual
building itself is worth the trip.
SCREAMIN’ GATOR ZIP LINE
AT GATORLAND
gatorland.com
SEAWORLD DISCOVERY COVE
discoverycove.com
Get up close like never before in the Dolphin
Lagoon, Freshwater Oasis or The Grand Reef
where you’ll experience aquatic wildlife and
choose from personal interactions. Swim
with dolphins, snorkel with exotic fish or
come face-to-face with a playful otter. Just
relax and explore.
HOLLYWOOD DRIVE-IN GOLF
hollywooddriveingolf.com
Based on vintage horror flicks and “little
green men” science fiction films, guests
putt through elaborate movie-style scenes
when they choose from two 18-hole minigolf courses. This state-of-the art attraction
is completely family friendly.
Kennedy Space Center Visitor Complex
Clip in and zip off on an exciting outdoor
adventure with the all-new Screamin’ Gator
Zip Line at Gatorland. Your journey will take
you along 1,200 feet of high-flying, heartpounding adventure from some of the finest
zip line towers in the world.
T
he list of hot spots for familyfriendly fun in Orlando is endless.
Plan ahead and make visiting these
parks and attractions the perfect way for
your family or friends to spend a day.
Visit Orlando
RIPLEY’S BELIEVE IT OR NOT!
ORLANDO ODDITORIUM
PLAN AHEAD FOR FAMILY FUN
IFLY ORLANDO INDOOR SKYDIVING
orlando.iflyworld.com
Experience true free-fall conditions, just
like skydiving, without having to jump out
of an airplane. It’s safe for kids (as young
as 3), challenging for adults and realistic
for skydivers. They provide all the gear and
personal instruction.
MARINELAND DOLPHIN ADVENTURE
marineland.net
Experience dolphins in a whole new way
with one of Marineland’s programs that
will bring you face to face with these
ocean ambassadors. You can swim with
dolphins, paint with them or simply touch
and feed them. Advance reservations are
recommended.
WILD FLORIDA WILDLIFE PARK
orlandotaste.com
wildfloridairboats.com
Experience the area’s culture and meaning
through food during a three-hour tour
throughout Orlando and Central Florida.
There are several tours to choose from,
each taking patrons to four or five handpicked restaurants or eateries for bite-sized
samplings of selected dishes that represent
both the chef and the city well.
Zebras, watusi, deer, tropical birds, sloths,
lemurs, monster alligators and many more
wild animals make this park their home. With
more than 150 native and exotic animals,
there is something for everyone to see.
KENNEDY SPACE CENTER
VISITOR COMPLEX
kennedyspacecenter.com
THE GREAT ESCAPE ROOM
thegreatescaperoom.com
Put your survival skills to the test as
you analyze clever clues to find secret
passageways and hidden compartments
during a 60-minute frantic search for
freedom. Will you be able to find a way out?
Wild Florida Wildlife Park
TANTALIZING TASTES & TOURS
See where the U.S. space program began,
and find out where it’s going. The space
center is the only place where you can
walk among the actual rockets of the
Mercury, Apollo and Gemini missions.
You also can meet a veteran astronaut
from NASA’s famous astronaut corps at
Astronaut Encounter, occurring daily.
37
Don’t Be
Fooled a
nd
Miss the
Savings
!
Save a
t Least
$200
Throug
h 11/11
!
Experience Magic at Your Fingertips with
Sessions OnDemand™ Premium
• Spellbinding Videos of Scientific
Sessions 2015 Presentations
• Captivating Cardiovascular
Science as Never Seen Before
• Downloadable PDFs of the
Presenter Slides and MP3 Audio
• Anywhere, Anytime Online
Access and Optional USB Drive –
Only $50 Plus Shipping
Purchase at sessionsondemand.org
Download the
Mobile
Meeting Guide
9:15 AM
Dashboard
Mobile app available at
scientificsessions.org/mobile
My Schedule
Educational
Sessions
Faculty
Abstracts
Unofficial
Programs
Science &
Tech Hall
Maps
Get It
At Sessions
Sessions
Daily News
AHA
Newsroom
Science
News
Updates
Social
Networks
AHA EVENTS 2015
Use the above QR code to download the meeting guide app
now or search and download the app from the
Google play or App Store by searching “AHA Events”!
DO-NOW CHECKLIST
NOW IS THE TIME TO MAKE YOUR PLANS TO
ATTEND SCIENTIFIC SESSIONS 2015 IN ORLANDO.
The American Heart Association’s Scientific Sessions has the best science and
is the leading cardiovascular conference for basic, translational, clinical and
population science in the United States. Make sure you don’t miss a thing.
❏ REGISTER TODAY
❏ RENEW YOUR MEMBERSHIP
❏ MAKE A MUST-SEE EXHIBITOR LIST
New this year: One registration fee! When
you register for Scientific Sessions 2015,
you receive access to all Scientific Sessions
programming, including the Resuscitation
Science Symposium and the Cardiovascular
Nursing Clinical Symposium. Plus, if
you register online, you’ll save $20. Visit
scientificsessions.org > Registration & Housing.
Make sure your AHA/ASA Professional
Membership is up to date. Join or become
a member by visiting my.americanheart.
org/professional/Membership/Membership_
UCM_316891_SubHomePage.jsp.
You’ll find the latest in technology, services
and products all inside the Science &
Technology Hall. Make note of the areas
dedicated to the tools and resources for your
business and practice.
❏ PLAN YOUR SCHEDULE
❏ DOWNLOAD OUR MOBILE APPS
Customize your learning by using areas of
interest designed to help you navigate the
meeting. There are 30 areas divided into five
categories — Basic, Clinical, Population,
Special Focus and Frontiers in Science —
allowing you to focus your education in
your specialty or expand your knowledge
in other areas. Visit scientificsessions.org >
Programming > 30 Programming Tracks.
Want your Scientific Sessions neatly
packaged to go? Get the Mobile Meeting
Guide app. It will help you navigate while
on site and provide instant access to event
information. Watch for the link to be
available in October by searching “AHA
Events” in Google play or the App Store.
Also now available in more sessions:
Conference Notes. Visit presentations and
take notes using Conference Notes — an
online, iPad- and laptop-friendly tool.
More information will be available soon at
scientificsessions.org.
❏ SET UP HOUSING
Whether your taste runs more Hilton or
Hard Rock, you’ll want to get your hotel
reservations locked down. To help in your
selection, AHA has sorted available hotels
by price, location and amenities. Visit
scientificsessions.org > Registration & Housing >
Hotel List and Map.
40
Scan this code
to register
REGISTER
ONLINE AT:
WWW.SYMPOSIAREG.COM/21513
*Compliments of
Apple watch & iPad drawing*
*See rules and regulations at www.symposiareg.com/21513
AGENDA
6:30 PM
Registration and Dinner
7:00 PM
Introduction
Co-Chairs: Valentin Fuster, MD, PhD and
Karol Watson, MD, PhD
7:10 PM
Clinical Evaluation of Women with Suspected
Ischemic Heart Disease: Addressing the
Challenges
7:30 PM
Are We Tailoring Antianginal Medications
to Our SIHD Patients, or Using Our
Favorite Drugs?
Benjamin Scirica, MD, MPH
7:50 PM
Case Presentation
C. Noel Bairey Merz, MD
8:05 PM
Revascularizing the Non-diabetic SIHD
Patient with Multivessel Disease: Clarifying
the Decision of PCI vs CABG
Valentin Fuster, MD, PhD
8:25 PM
Case Presentation
Deepak Bhatt, MD, MPH
8:40 PM
Question-and-Answer
9:00 PM
Conclusion of Program
AN EXPERT FORUM:
CO-CHAIRS
Valentin Fuster, MD, PhD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
FACULTY
C. Noel Bairey Merz, MD
Cedars-Sinai Medical Center, Heart Institute
Los Angeles, California
Monday, November 9, 2015
Registration and Dinner: 6:30 PM – 7:00 PM
Symposium: 7:00 PM – 9:00 PM
Rosen Centre Hotel
Grand Ballroom C
Deepak Bhatt, MD, MPH
Harvard Medical School
Boston, Massachusetts
Benjamin Scirica, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
9840 International Drive
Orlando, Florida
This event is not part of the official
Scientific Sessions 2015 as planned
by the AHA Committee on Scientific
Sessions Programming.
This activity is supported by an
independent educational grant from
Gilead Sciences Medical Affairs.
This program is
sponsored by
What more is there
to learn about platelet
activation and
aggregation?
Find out at
Booth 701
Copyright © 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. CARD-1141095-0005 08/15

Publication - American Heart Association

Transcription

Similar documents

November Newsletter - J. Douglas Hodgson Elementary School

scare fair - Keiser University

Water Shortage? Salty Water?

Real Estate Classes for $99 Call Today!

Newsletter 09.10.2015

AHA and Google Life Sciences invest $50 million to transform heart

Columbia Facilities M aintenance Expo

Elpaso all night madness flyerpage1

December - Apoorva Mandavilli

The Agnus Dei - Episcopal Church of the Good Shepherd